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Gastric cancer is largely a fatal disease associated with high incidence and mortality in most 
Asian populations where it imposes a huge disease and economic burden on the society. Given 
that the efficacy of gastric cancer treatment is still unsatisfactory, efforts have been directed at its 
prevention. Presently secondary prevention measures aiming for early detection, namely 
screening and surveillance, have assumed an increasingly important role for gastric cancer control.  
 
Mass screening targets the asymptomatic subjects in the general population at high risk of gastric 
cancer. Surveillance focuses on the people with precancerous lesions who are therefore already in 
the process of gastric cancer development. Studies have demonstrated that both screening and 
surveillance are effective in detecting the malignancy at an earlier stage and consequently 
achieving longer patient survival. However, for public health practice to translate these research 
findings into health benefits, more information is needed to investigate the cost of illness, clinical 
outcome and ultimately cost-effectiveness ratio. These studies belong to health services research 
(HSR).  
 
This PhD project was undertaken to conduct HSR studies on the secondary prevention of gastric 
cancer, particularly endoscopic surveillance. Besides its value as an academic pursuit, this PhD 
project aims to provide scientific evidence to address the issues regarding implementing an 
endoscopic surveillance program for gastric cancer in the Singapore Chinese population. The 
cost-effectiveness data may also help health authorities to make an informed decision on the 
worth of investing in such a public health program for Singapore.  
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Nested within the Gastric Cancer Epidemiology, Clinical and Genetics Program (GCEP), three 
studies were designed for this project. Each study has value in its own right and at the same time, 
they together form a coherent series to answer the overriding question of this project: Is 
endoscopic surveillance for gastric cancer cost-effective in the Singapore healthcare system? For 
the benefit of readers and reviewers, the thesis is organized into seven chapters as follows.   
 
Chapter I introduces basic clinical and epidemiological knowledge about gastric cancer, and two 
commonly used clinical outcomes in cancer research, namely, survival rate and quality of life. 
Readers can catch an overview of gastric cancer. This chapter aims to convey the message that 
gastric cancer is of major public health significance in Singapore and worldwide.    
 
Chapter II introduces the key definitions and concepts regarding gastric cancer prevention. The 
natural history of gastric cancer and the theory of secondary prevention are explained. I also 
summarize the current state of gastric cancer prevention highlighted by different studies.   
 
Chapter III presents the first study of this project which is a cost of illness study based on 
empirical data from the GCEP in delivering endoscopic surveillance. Unlike a conventional cost 
of illness study which covers the clinical phase starting from diagnosis to post-diagnosis 
treatment until the patient’s death, our study sheds light on the cost increment before the 
diagnosis, an area rarely touched to date. As a stand-alone cost analysis, we elucidated the 
mechanisms underlying the temporal trend of cost generation. Health policy makers can use this 
information in the planning of a long-term program. To enhance the coherence of this project, 
results have been directly used in the final model of the cost-effectiveness analysis.  
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Chapter IV presents the second study which is a quality of life study in Chinese patients with 
gastric cancer. We validated a gastric cancer specific quality of life instrument called Functional 
Assessment of Cancer Therapy-Gastric module (FACT-Ga). This validation study paves the way 
for future quality of life research for gastric cancer in Chinese populations. At the same time, the 
scores of the European Quality of Life Five Dimensions (EQ-5D) instrument derived by this 
study have been inputted to reflect the utilities of gastric cancer patients in the final cost 
effectiveness analysis.  
 
The third study, a cost-effectiveness analysis using the Markov model, is presented in the 
subsequent three chapters.  
 
Chapter V gives a detailed description about how the Markov model was built using TreeAge 
software. To highlight transparency as one of the key criteria for model validity, I have explained 
step by step the clinical assumptions and pros and cons of the data selected. Readers are able to 
have a clear picture about the model construction process from a simple diagram to a complicated 
Markov model.  
 
Chapter VI presents the cost-effectiveness ratio and its heterogeneity at base case analysis. The 
input parameters are examined extensively by deterministic and probabilistic sensitivity analysis. 
Results are presented for the parameters with significant impact on net health benefit or 
probability of being cost-effective.   
 
Chapter VII discusses the findings of the Markov model from the perspective of the healthcare 
system.  The cost-effectiveness of 2-yearly endoscopic screening, annual endoscopic surveillance 
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and no endoscopic intervention were compared. The model recommended surveillance to be the 
cost-effective strategy in prevention of gastric cancer in Singapore Chinese. Several parameters 
are identified as influential factors for establishing a successful endoscopic surveillance program. 




LIST OF TABLES 
 
 
Table 1-1. Subsite distribution of gastric cancer in the stomach (2003-2007) ................................ 2 
 
Table 1-2. TNM staging system for gastric cancer .......................................................................... 4 
 
Table 1-3. Clinical staging system for gastric cancer ...................................................................... 6 
 
Table 1-4. Basic statistics of gastric cancer in Singaporean Chinese (2003 – 2007) ..................... 10 
 
Table 1-5. 5-year survival rates of Singapore Chinese (%) (1998-2002) ...................................... 16 
 
Table 1-6. Utility of gastric cancer patients used in cost-effectiveness studies ............................. 17 
 
Table 3-1. Cost components and cost estimation of the GCEP (2004-2010) ................................ 35 
 
Table 3-2. Yearly patient volume of GCEP (2004-2010) .............................................................. 38 
 
Table 3-3. Characteristics of the study cohort and sample ............................................................ 38 
 
Table 3-4. GEE models fitting temporal trends of cost indices and comparison of subgroup trends. 
 ....................................................................................................................................................... 43 
 
Table 4-1. Utility weights for EQ-5D domains.............................................................................. 56 
 
Table 4-2. Demographic and clinical characteristics of the sample ............................................... 58 
 
Table 4-3: Score distributions, ceiling effect, reliability and item-scale convergence of the FACT-
Ga and EQ-5D ............................................................................................................................... 60 
 
Table 4-4. Sensitivity of FACT-Ga scores and EQ-5D utility to clinical severity ........................ 60 
 
Table 4-5. Multitrait-multimethod correlations matrix between EQ-5D domains and FACT-Ga 
subscales ........................................................................................................................................ 62 
 
Table 5-1. Endoscopy frequency recommended for endoscopic surveillance for gastric cancer .. 69 
 
Table 5-2. Gastric cancer incidence reported by the Singapore Cancer Registry (1/100,000) ...... 84 
 
Table 5-3. Gastric cancer incidence by age and gender in the Markov model (1/100,000) .......... 85 
 
Table 5-4. Annual probability of gastric cancer survival by clinical stage (%) ............................. 93 
 
Table 5-5. Probability of dying at each age of the Singapore Chinese population ........................ 96 
 
Table 5-6. Probability composition of gastric cancer patients surviving through a given year ..... 98 
 




Table 5-8. Operational cost for a screening or surveillance program .......................................... 101 
 
Table 5-9. Algorithm of stage specific gastric cancer treatment ................................................. 102 
 
Table 5-10. Diagnostic cost and treatment cost by clinical stage ................................................ 102 
 
Table 5-11. Stage-specific utility of gastric cancer patients ........................................................ 104 
 
Table 6-1. Reduction in gastric cancer related death by the surveillance and screening strategies
 ..................................................................................................................................................... 108 
 
Table 6-2. Heterogeneity of the three strategies by age and gender ............................................ 111 
 
Table 6-3. Parameters impactful on net health benefit of surveillance strategy identified by 
sensitivity analysis ....................................................................................................................... 113 
 
Table 6-4. Distributions assigned to parameters in probabilistic sensitivity analysis .................. 123 
 




LIST OF FIGURES 
 
Figure 1-1. Anatomy of the stomach ............................................................................................... 1 
 
Figure 1-2. Histological layers of stomach wall .............................................................................. 3 
 
Figure 1-3: Geographic distribution of gastric cancer incidence Rate ............................................. 8 
 
Figure 1-4: Geographic distribution of gastric cancer mortality ...................................................... 9 
 
Figure 1-5. Age specific gastric cancer incidence by sex .............................................................. 10 
 
Figure 1-6. Declining trends in gastric cancer mortality and incidence for males ......................... 11 
 
Figure 1-7. Declining trends in gastric cancer mortality and incidence for females ..................... 12 
 
Figure 2-1. Carcinogenesis for Gastric Cancer .............................................................................. 19 
 
Figure 2-2. Clinical consequences of H. pylori infection .............................................................. 20 
 
Figure 2-3. Natural history of a disease ......................................................................................... 23 
 
Figure 3-1: Phases and time frame of the GCEP ........................................................................... 33 
 
Figure 3-2. Cost Structure of the GCEP ........................................................................................ 34 
 
Figure 3-3. Temporal trends (2004-2010) of cost indices for the whole sample. .......................... 39 
 
Figure 3-4. Temporal trends (2004-2010) of cost indices for the age subgroups. ......................... 40 
 
Figure 3-5. Temporal trends (2004-2010) of cost indices for the gender subgroups. .................... 41 
 
Figure 3-6. Temporal trends (2004-2010) of cost indices for the risk subgroups. ......................... 42 
 
Figure 4-1. Sampling Frame of quality of life study ...................................................................... 53 
 
Figure 4-2. Subject recruitment process ........................................................................................ 54 
 
Figure 4-3. Factor structure of FACT-G ........................................................................................ 55 
 
Figure 4-4. Factor structure of FACT-Ga ...................................................................................... 55 
 
Figure 5-1. Biopsy sites during endoscopy examination in screening and surveillance ................ 71 
 
Figure 5-2. Overview of the surveillance strategy ......................................................................... 73 
 
Figure 5-3. Overview of clinical pathway of target population developing gastric cancer ........... 74 
xiii 
 
Figure 5-4.  Overview of clinical pathway of present situation without gastric cancer prevention
 ....................................................................................................................................................... 76 
 
Figure 5-5. Expected effect of stage-shift by gastric cancer prevention programs ........................ 77 
 
Figure 5-6. Basic TreeAge tree comparing screening, surveillance and no OGD intervention ..... 77 
 
Figure 5-7. Markov Model for the no OGD intervention strategy ................................................. 78 
 
Figure 5-8. Markov Model for the screening strategy ................................................................... 79 
 
Figure 5-9. Markov Model for the surveillance strategy ............................................................... 80 
 
Figure 5-10. Gastric cancer development in the general population with no OGD intervention... 83 
 
Figure 5-11. Gastric cancer detected during years without follow-up OGD ................................. 86 
 
Figure 5-12. Gastric Cancer detected by screening OGD .............................................................. 86 
 
Figure 5-13. Gastric cancer development at baseline of the general population ........................... 88 
 
Figure 5-14. Gastric cancer development in the low risk cohort ................................................... 90 
 
Figure 5-15. Gastric cancer development in the high risk cohort .................................................. 91 
 
Figure 5-16. Gastric cancer diagnosis and treatment with simulation of in-hospital mortality ..... 92 
 
Figure 5-17. Gastric cancer diagnosis and treatment without simulation of in-hospital mortality 92 
 
Figure 5-18. Stage specific gastric cancer survival ........................................................................ 94 
 
Figure 5-19. Death states in the Markov model ............................................................................. 94 
 
Figure 5-20. Co-mortality of the target population ........................................................................ 95 
 
Figure 5-21. Death for other reasons of GC patients ..................................................................... 97 
 
Figure 5-22. Stage distribution of gastric cancer patients diagnosed under usual care ................. 99 
 
Figure 5-23. Stage distribution of gastric cancer patients detected by follow-up OGD .............. 100 
 
Figure 5-24. Cost assignment in Markov trees ............................................................................ 103 
 
Figure 6-1. Age-specific gastric cancer incidence of Singapore Chinese .................................... 106 
 
Figure 6-2. Age-specific all-cause mortality of Singapore Chinese (original vs. model estimates)
 ..................................................................................................................................................... 107 
 
Figure 6-3. Comparing the cost effectiveness of no OGD intervention, ..................................... 109 
 




Figure 6-5. Net Health Benefit variation across the range of age starting follow-up .................. 115 
 
Figure 6-6. Net Health Benefit variation across the range of willingness-to-pay ........................ 116 
 
Figure 6-7. Net Health Benefit variation across the range of odds ratio of high risk subjects in the 
surveillance strategy..................................................................................................................... 117 
 
Figure 6-8. Net Health Benefit variation across the range of proportion of program cost of 
operational cost ............................................................................................................................ 118 
 
Figure 6-9.  NHB variation across the range of utility of Stage 1 gastric cancer patients ........... 119 
 
Figure 6-10. Net Health Benefit variation across the range of follow-up OGD cost ................... 120 
 
Figure 6-11. Net Health Benefit variation across the range of baseline OGD cost of the 
surveillance strategy..................................................................................................................... 121 
 
Figure 6-12: Net Health Benefit variation across the range of prevalence of gastric precancerous 
lesions .......................................................................................................................................... 122 
 
Figure 6-13. Simulated Gamma (310, 352) of the utility of Stage 1 patients .............................. 124 
 
Figure 6-14. Simulated Gamma (151, 176) of the utility of Stage 2 patients .............................. 125 
 
Figure 6-15. Simulated Gamma (60, 77) of the utility of Stage 3 patients .................................. 125 
 
Figure 6-16. Simulated Gamma (72, 106) of the utility of Stage 4 patients ................................ 125 
 
Figure 6-17. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding the utility of Stage 2 patients .............................................................. 126 
 
Figure 6-18. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding the utility of Stage 3 patients .............................................................. 127 
 
Figure 6-19. Probability of being cost-effective of three strategies when accounting for 
uncertainties surrounding the utility of Stage 4 patients .............................................................. 127 
 
Figure 6-20. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding the utility of Stage 4 patients .............................................................. 128 
 
Figure 6-21. Simulated input distribution representing the proportion of Stage 1 cases among  
gastric cancer patients diagnosed under usual care ...................................................................... 129 
 
Figure 6-22. Simulated input distribution representing the proportion of Stage 1 cases among the 
gastric cancer cohort detected by follow-up endoscopy .............................................................. 129 
 
Figure 6-23. Probability of being cost-effective of three strategies when accounting for 




Figure 6-24.  Probability of being cost-effective for the three strategies when accounting for 
uncertainties surrounding the stage composition of gastric cancer cohort................................... 130 
 
Figure 6-25. Simulated input distribution representing the odds ratio of high risk subjects in the 
surveillance strategy..................................................................................................................... 131 
 
Figure 6-26. Probability of being cost-effective for the three strategies given uncertainties 
surrounding the odds ratio ........................................................................................................... 132 
 
Figure 6-27. Simulated input distribution of prevalence of precancerous lesions ....................... 132 
 
Figure 6-28. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding prevalence of precancerous lesions. ................................................... 133 
 
Figure 6-29. Probability of being cost-effective for the three strategies given the age variation 
among individuals of the target population.................................................................................. 134 
 
Figure 6-30. Probability of being cost-effective of the three strategies accounting for uncertainties 




LIST OF ABBREVIATIONS  
  
 ASIR: Age Standardized Incidence Rate 
ASMR: Age Standardized Mortality Rate 
ASRS: Age Standardized Relative Survival 
CI: Confidence Interval 
EGC: Early Gastric Cancer  
EQ-5D: European Quality of Life Questionnaire- 5 Dimensions 
FACT: Functional Assessment of Cancer Treatment 
FACT-Ga: Functional Assessment of Cancer Treatment – Gastric 
PWB: Physical Well-Being  
EWB: Emotional Well-Being  
SWB: Social Well-Being  
FWB: Functional Well-Being  
  GCS: gastric cancer subscale  
GC: Gastric Cancer 
GCEP: Gastric Cancer Epidemiology Clinical & Genetic Program 
GEE: Generalized Estimation Equation 
H. pylori: Helicobacter Pylori  
ICER: Incremental Cost-Effectiveness Ratio 
NHB: Net Health Benefit 
xvii 
 
NUH: National University Hospital  
OGD: Oesophago-Gastro-Deuodenoscopy 
OR: Odds Ratio 
PSA: Probabilistic Sensitivity Analysis 
QALY: Quality Adjusted Life Year 
QoL: Quality of Life  




CHAPTER I: GASTRIC CANCER BURDEN 
 
1.1 Gastric Cancer - Definition and Classification  
1.1.1 Gastric cancer definition 
 
Gastric cancer (GC) refers to cancerous malignancy arising from any part of the stomach. In the 
literature and clinical practice, the term GC does not refer to a single disease, but rather different 
cancerous diseases affecting a single organ. Although GC is a heterogeneous disease covering 
lymphoma, leiomyosarcoma, carcinoid, adenocarcinoma and squamous cell carcinoma, the most 
frequently encountered histological type is mucosal adenocarcinoma which comprises more than 90% 
of all GC cases worldwide (Forman and Burley 2006) and locally in Singapore (Singapore Cancer 
Registry Committee 2010). Therefore, GC refers to the adenocarcinoma most of time in this thesis.   
 
Figure 1-1. Anatomy of the stomach 
 
The stomach is arbitrarily divided into five anatomical parts (Figure 1-1) labeled from proximal to 
distal ends as cardia, fundus, body, pylorus and antrum. These labels help us locate and describe GC 
lesions. The sites where GC occurs are also relevant to histological type and thus prognosis of patients. 




Table 1-1. Subsite distribution of gastric cancer in the stomach (2003-2007) 
Subsite Male Female 
Cardia 249 116 
Pylorus 72 35 
Antrum 268 187 
Fundus 19 13 
Body 77 61 
Body (less curvature) 124 80 
Body (greater curvature) 42 34 
Other 68 29 
Not otherwise specified 456 330 
       (Singapore Cancer Registry 2011) 
 
1.1.2 Gastric cancer staging and histological classification  
 
Cancer staging is a critical step in clinical management and cancer-based public health programs. The 
stage of a cancer patient measures the extent of disease spread and is related to treatment protocol, 
cancer progression and future prognosis.  
 
1.1.2.1 TNM staging system for gastric cancer  
 
Like most solid tumors, GC Stage is rated according to TNM system. TNM staging system was 
developed in 1940’s and has been globally recognized as the international standard for cancer 
classification. Currently it is maintained by American Joint Committee on Cancer (AJCC). TNM 
staging system defines criteria to measure the severity of a tumor disease as follows.  
1. T (tumor) refers to the size of the primary tumor mass, which could be the original tumor 
and/or nearby tissues when involved.  
2. N (node) refers to lymph nodes close to the original organ or tissue. The cancer is called 
regional if nearby nodes are invaded.  
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3. M (metastasis) refers to tumor’s spread to a distant organ or system 
To facilitate the understanding how TNM system works with GC disease, the histology of stomach 
wall is presented in Figure 1-2. The detailed explanation of TNM system for GC is presented in Table 
1-2. 
 





Table 1-2. TNM staging system for gastric cancer  
Parameters  Description 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis 
Carcinoma in situ: intraepithelial tumour 
 without invasion of the lamina propria 
T1 
Tumour invades lamina propria, 
 muscularis mucosa, or submucosa 
T1a Tumour invades lamina propria or muscularis mucosa 
T1b Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 
Tumour penetrates subserosal connective tissue 
 without invasion of visceral peritoneum or adjacent structures 
T4 Tumour invades serosa (visceral peritoneum) or adjacent structures 
T4a Tumour invades serosa (visceral peritoneum) 
T4b Tumour invades adjacent structures 
Regional lymph nodes (N) 
NX Regional lymph node(s) cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 regional lymph nodes 
N2 Metastasis in 3-6 regional lymph nodes 
N3 Metastasis in seven or more regional lymph nodes 
N3a Metastasis in 7-15 regional lymph nodes 
N3b Metastasis in 16 or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 





1.1.2.2 Clinical staging system for gastric cancer  
 
Based on the TNM system, a clinical staging system was developed and adopted by clinicians. The 
two systems are used in parallel in clinical practice to guide algorithms for stage-specific treatment. 
The clinical staging system for GC is presented in Table 1-3.   
 
The term early gastric cancer (EGC) has been widely used in recent decades as the interest in 
screening or surveillance for GC grew. EGC is designated for the GC lesions confined to mucosa 
and/or submucosa irrespective of lymph node involvement or tumor size. In light of the TNM system, 
EGC refers to any GC case with T1 primary tumor. In clinical classification system, EGC normally 
refers to all Stage 0 and Stage 1 patients and part of Stage 2 GC patients. Clinically, EGC is a strong 
indication of endoscopy-based procedures as the first-line treatment. The diagnosis of EGC envisions 




Table 1-3. Clinical staging system for gastric cancer   
Stage Tumour  Node Metastasis 
Stage 0 Tis N0 M0 
Stage 1 
IA T1 N0 M0 
IB T2 N0 M0 
  T1 N1 M0 
Stage 2 
IIA T3 N0 M0 
 
T2 N1 M0 
  T1 N2 M0 
IIB T4a N0 M0 
 
T3 N1 M0 
 
T2 N2 M0 
  T1 N3 M0 
Stage 3 
IIIA T4a N1 M0 
 
T3 N2 M0 
 
T2 N3 M0 
IIIB T4b N0 M0 
 
T4b N1 M0 
 
T4a N2 M0 
  T3 N3 M0 
IIIC T4b N2 M0 
 
T4b N3 M0 
 
T4a N3 M0 
Stage 4 IV Any T Any N M1 
(Washington 2010) 
 
1.1.2.3 Lauren system for gastric cancer  
 
Another simple but well accepted classification system is called Lauren system, which is specifically 
designed for gastric adenocarcinoma (Lauren 1965).  Based on the histological status of gastric 
mucosa, the Lauren system categorizes GC into intestinal type, diffuse types and mixed type. The 
intestinal type of GC is called “epidemic” type owing to the fact that it arises from the gastric mucosa 
and retains glandular structure and cellular polarity. This type has been the main histological form of 
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GC  in the world (Bertuccio et al. 2009). The diffuse type of GC disease differs in two important 
aspects from the intestinal type. It shows an invasive growth pattern and is thought to be closely 
related to genetic polymorphism. The diffuse type accounts for a small percentage of GC cases 
(Bertuccio et al. 2009; Singapore Cancer Registry 2011). Therefore, this thesis took intestinal type to 
illustrate the benefit of preventive programs.   
 
1.2 Global Burden of Gastric Cancer 
 
GC remains a global public health concern. Every year, there are around one million GC cases and 
700,000 GC related deaths , which account for 8% of the total cancer cases and 10% of total cancer 
deaths in the world respectively (Jemal et al. 2011). With a fatality-to-case ratio of 70%, GC is a 
deadly disease making it the second most common cause of death due to cancer worldwide. Although 
more than 70% of incident cases occur in developing countries and 42% in China alone, age-
standardized incidence are comparable between developed and developing countries.  
 
1.2.1 Gastric cancer incidence   
 
Recent decades have witnessed a substantial decrease of GC incidence in the world. The reasons are 
not yet clear. Data have shown that this decrease was driven by gastric carcinoma located in the distal 
stomach. Although it is believed that this declining trend will continue in the near future, it would not 
be able to reduce the GC burden. Instead, the overall GC number most likely would increase for 
several decades to come as a result of population growth and increased proportion of older people in 
most countries (Forman and Burley 2006).  
 
There is considerable geographic variation in GC incidence across countries and within an area. The 
populations with age-standardized incidence greater than 20/100 000 are categorized as high risk. The 
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intermediate risk countries have an incidence between 11 and 20/100 000 inclusive. If age-
standardized incidence is below 10/100 000 population, the country is categorized as with low GC 
risk (Ferlay J 2004). The  high-risk  areas  include  East  Asia,  Eastern  Europe,  and  parts  of Central 
and South America (Jemal et al. 2011), while GC risk is low in Southern Asia, North and East Africa, 
North America, Australia, and New Zealand (Figure 1-3).  
 
Figure 1-3: Geographic distribution of gastric cancer incidence rate 
Unit: (1/100,000) (Forman and Burley 2006) 
 
1.2.2  Gastric cancer mortality  
Following the downward trend seen in incidence, GC mortality has also declined over time globally. 
The declining mortality has been attributed to the declining incidence as there has been no significant 
advance in GC treatment over the same period. Currently the prognosis of a GC patient is very poor. 
When gastric symptoms manifest, it is often too late for GC treatment to be effective.  
 
Like incidence, the mortality of GC has strong geographical and ethnical characteristics. Age-
standardized mortality is high in Asian countries. Korea and Japan have the highest GC specific 
mortality in the world. However, GC mortality is not directly associated with the level of economic 





Figure 1-4: Geographic distribution of gastric cancer mortality   
Unit: 1/100,000 (Forman and Burley 2006) 
 
1.3 Singapore Burden of Gastric Cancer   
1.3.1 Gastric cancer incidence  
 
Similar to the downward trend of GC incidences documented in other parts of the world, GC 
incidence declined steadily in Singapore with an average annual rate of 2.7% in males and 2.2% in 
females respectively. Now it ranks 5th and 8th among males and females in terms of cancer morbidity.  
 
Singapore is a multi-racial society comprising Chinese, Malay and Indian. Chinese account for 91% 
of all GC cases diagnosed in 2003-2007. The GC risk for Malay males and Indian males are 32% (CI, 
0.25 – 0.42) and 55% (CI, 0.33 - 0.89) of that for Chinese respectively. For females, age-standardized 
incidence for Malays and Indians are 37% (CI, 0.26-0.51) and 60% (CI, 0.42-0.86) of that for Chinese 

















   Male 5 1235 19 16 .3 6.6 
Female 7 811 12.2 8.1 4.1 
Mortality  
   Male 4 927 10.8 9.8 7.9 
Female 4 624 6.7 7.1 5.1 
 (Singapore Cancer Registry Committee 2010) 
*
ASR: age standardized rate.   
†
 Percentage of incidence and mortality of all cancers in Singapore  
 
GC is associated with demographic variables. As shown in Figure 1-5, the GC risk of males doubles 
that of females; age is positively associated with GC risk and there is a sharp increase of GC 
incidence after 50 year old. Considering race, age and gender as indicators for susceptibility, elderly 
Chinese males are the most susceptible population for GC in Singapore.  
 
 
Figure 1-5. Age specific gastric cancer incidence by sex (2003-2007) 







1.3.2 Gastric cancer mortality  
The declining trend seen in the incidence was also observed in the GC mortality.  Documented by 
Singapore Cancer Registry, the mortality has fallen by half to two-thirds over a period of 34 years for 
females and males alike. During the study period of 2003 – 2007, GC contributed 927 deaths and 624 
deaths in male and female population respectively, the 4
th
 ranking cancer related death for both 
genders in Singapore. The trends of GC mortality, incidences and relative survival were presented for 
both genders in Figure 1-6 and Figure 1-7.  
 
Figure 1-6. Declining trends in gastric cancer mortality and incidence for males  






Figure 1-7. Declining trends in gastric cancer mortality and incidence for females   
ASRS, age standardized relative survival; ASIR, age standardized incidence rate; ASMR, age standardized 
mortality rate 
 
1.4 Risk Factors for Gastric Cancer Development 
 
Helicobacter pylori (H. pylori), a common inhabitant of the human stomach, is the infective agent 
categorized by World Health Organization as class I carcinogen for GC development. H. pylori 
infection specifically increases distal GC in the antrum and body of the stomach where the vast 
majority of GC cases is diagnosed. GC in proximal stomach is not related to H. pylori infection. In a 
pooled analysis of 12 prospective studies, a six-fold increased GC risk was demonstrated 
(Helicobacter pylori and Cancer Collaborative Group 2001).  H. pylori infection will be discussed 
further in Chapter II. 
 
Dietary factors have long been proposed as important contributors to GC development and death. 
Dietary intake of salt, which was commonly used to preserve vegetables in Korea and Japan in old 
days, has been associated with increased GC incidence and GC mortality. Independent of other risk 
factors, salt intake is strongly correlated with GC specific mortality. The Pearson’s correlation 
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coefficients were 0.7 in men and 0.74 in women both with statistical significance (P<0.001)  
(Joossens et al. 1996). Two studies conducted in Japan illustrated the elevated GC incidence in 
persons with excessive salt intake through pickled vegetables and salted fish (Shikata et al. 2006; 
Tsugane 2005).  
 
In contrast to salt intake with food, a diet rich in fruit and vegetables was found to be protective from 
GC. A meta-analysis (Riboli and Norat 2003) and an observation study (Parkin et al. 2005) have 
proved that consumption of fresh fruits and vegetables would reduce GC risk with varying effects. A 
44% reduction in GC incidence has been reported in another large prospective cohort study 
(Larsson,Bergkvist and Wolk 2006).  
 
Smoking is an established causal factor for GC. A dose-response relationship of GC development to 
cigarette smoking was presented in an analysis by the European prospective investigation into cancer 
& nutrition study (Gonzalez et al. 2003). Smokers are 1.53 times more likely to develop GC 
(Ladeiras-Lopes et al. 2008) and 1.43 times more likely to die of it (Smyth et al. 2012).  Alcohol use 
was only recently implicated to be a significant behavior factor for GC incidence (Tramacere et al. 
2012).  
 
Environmental factors also play an important role in GC development. Migration studies showed that 
first generation immigrants of high risk population still have higher risk than local population. The 
later generations, although sharing the same diet and behaviors, had a reduced risk at a level similar to 
the local residents (Kamineni et al. 1999).  
 
Relatives of a GC patient have an increased risk of GC, which suggests the genetic mechanisms. A 
cohort of genes were identified capable of increasing human susceptibility to GC (Saeki et al. 2013). 
Germline mutations in MLH1 and MSH2 are confirmed with increased risk of intestinal 
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adenocarcinoma (Aarnio et al. 1997).  Germline mutations in CDH1 will cause hereditary diffuse type 
of GC, which is characterized by early onset of the disease and may require prophylactic gastrectomy 
(Pharoah,Guilford and Caldas 2001).  The mutation responsible for familial adenomatous polyposis is 
associated with antral adenocarcinoma in Japanese and Korean populations.  
 
1.5 Clinical Management and Clinical Outcomes of Gastric Cancer 
  
1.5.1  Gastric cancer treatment  
GC management depends on the stage of the disease and general health of the patient. For cases in 
early stages (Stage 1 & 2) where the aim is a cure, surgery is the primary treatment modality with 
curative intent. The gastrectomy removes partial or entire stomach and the adjacent lymph nodes to 
achieve complete removal of the tumor tissues. For Stage 3 or Stage 4 cases, surgeries are used mostly 
to relieve symptoms, such as dysphasia and chronic pain. Patients operated for a curative intent 
accounts for only 30-50% of all clinical patients undergoing surgical procedures (Parkin,Pisani and 
Ferlay 1999).  
 
Given the limit of the surgery, systemic treatment with adjuvant and neoadjuvant chemotherapy plays 
an important role. These drugs are effective in shrinking the tumor mass for better surgical outcome, 
decreasing the chance of recurrence, prolonging survival life and improving quality of life.    
 
Recently, endoscopy-based procedures, namely, endoscopic mucosal resection and endoscopic 
submucosal dissection, have been developed and quickly spread around the world. These procedures 
are good alternatives to traditional open surgery for EGC. Studies have shown that these procedures 




The GC treatment advances very fast. For the treatment of EGC, endoscopic mucosal resection and 
endoscopic submucosal dissection are widely used in Asian countries including Singapore (Ang, Khor 
and Gotoda 2010). Novel surgical procedures like sentinel node navigation surgery have started 
clinical applications in recent years (Wang et al. 2012). For advanced GC cases, systemic medical 
management remains the mainstay. Besides traditional chemotherapy, various immunotherapeutic 
strategies have been developed which include epithelial growth factor receptor inhibitor, T-cell-based 
antigastric cancer treatment, antiangiogenic agents, apoptosis promoters and specific immunotherapy 
(Amedei et al. 2011).  
 
Despite these advances in GC treatment, stage-specific survival has remained steady for the past 
decade. The mortality reduction parallels the decline in incidence which strongly indicates a causal 
relationship. Early detection and early prevention, in comparison with treatment, should assume a 
bigger role for improved GC control in the future.   
 
1.5.2 Clinical outcome 1 - survival rate 
 
GC survival is stage-specific. There is a huge difference in outcomes between EGC and patients with 
advanced disease. The 5-year survival rate has achieved 90% for EGC in several populations (Lello, 
Furnes and Edna 2007; Tsubono et al. 2000), while it remains between 10 and 20% for Stage 4 GC 
patients (Lello, Furnes and Edna 2007). In Singapore, Koong et al reported 5-year survival rates of 
90%, 70%, 40%, and 0% for Stage 1, Stage 2, Stage 3 and Stage 4 cases respectively (Koong et al. 
1996). Singapore Cancer Registry data showed the distinctions of survival rates between local, 
regional and metastatic GC patients (Table 1-5). None of Stage 4 patients survived two years after 
diagnosis in Singapore.   
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Male  Female 
Local Regional Local Regional 
50-64 64 8.6 75.6 22.5 
65-74 47.8 11.7 44.3 8.6 
75- 15.7 0  22.4 0 
 
Recent years have witnessed great improvement in GC survival. In Singapore, the 5-year age 
standardized relative survival (ASRS) more than doubled in both males and females for the past 40 
years. A similar trend was observed in other regions and populations (Bertuccio et al. 2009). Early 
detection of GC cases was speculated to be the major reason responsible for the survival improvement. 
The strongest evidence comes from Japan. It was reported that the national GC screening program 
detected most GC cases when they were still at early stage (Mizoue et al. 2003). As a result, the 
overall 5-year survival rate of Japanese patients is the highest in the world (Leung et al. 2008). 
Although Singapore has not established mass screening for GC, the rapid development in healthcare 
infrastructure offers easy access to endoscopic investigation, which has higher sensitivity and 
specificity than conventional approach in diagnosing the malignancy. Consequently, GC patients 
would be diagnosed in the earlier stages and receive curative treatment. Hence, the proportion of early 
GC patients has increased and at the same time, the 5-year survival rates have improved.  
 
1.5.3 Clinical outcome 2 - quality of life 
Quality of life (QoL), in addition to 5-year survival rate, has been advocated as another primary 
outcome for GC (Langenhoff et al. 2001). QoL measures the impact on the individual patients’ 
perceived well-being due to disease and related treatment. In the case of GC, QoL has significant 
associations with clinical stage (Huang et al. 2007), type of surgery (Lawrence 2008), adjuvant 
therapy (Sadighi et al. 2006; Sadighi et al. 2009) and purpose of treatment (Sadighi et al. 2006; 




QoL can be measured by generic and condition specific QoL instruments. The results from generic 
QoL questionnaires can produce utility scores indicating the overall health status of a GC patient. 
These scores can be used for comparisons between GC patients and other disease groups. GC-specific 
instruments are designed to investigate detailed information specifically relevant to GC. Its scores are 
unique and therefore not appropriate for a cross-disease comparison. However, being more sensitive 
to changes due to the disease under investigation, GC-specific score is very useful to monitor disease 
progression or effect of treatment. Functional assessment of cancer therapy-gastric (FACT-Ga) and 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for 
stomach cancer are two commonly used disease specific QoL instruments in GC studies.  
 
Assessment of QoL is also crucial for economic evaluation, particularly for cost-utility analysis. The 
validity of an economic model is greatly determined by its utility scores. Ideally, utility scores come 
from a QoL study of the target populations evaluated with a reliable instrument. Table 1-6 lists the 
utility scores used in cost-effectiveness analyses evaluating different GC screening strategies. Six of 
seven studies failed to show the instrument used to generate the utility scores. Therefore, the huge 
variation among the utility scores cannot be safely assumed to be the true QoL variation caused by the 
GC disease. This also makes one speculate that the reported cost-effectiveness may be the result of 
arbitrary selection of the utility scores.  
Table 1-6. Utility of gastric cancer patients used in cost-effectiveness studies  
Gastric Cancer Patient Type Utility Instrument Reference 
Advanced gastric cancer  0.797 EQ-5D 
(Shiroiwa,Fukuda and 
Shimozuma 2011) 
Gastric cancer 0.49 N/A (Yeh,Ho and Hur 2010) 
Gastric cancer 0.49 N/A (Yeh et al. 2010) 
Gastric cancer 0.5 N/A (Xie et al. 2009) 
Gastric cancer 0.55 N/A (Rupnow et al. 2009) 
Gastric cancer 0.38 N/A (Xie et al. 2008) 
Gastric cancer Stage 4 0.4 N/A (Dan,So and Yeoh 2006) 
Gastric cancer Stage 3 0.5 N/A (Dan,So and Yeoh 2006) 
Gastric cancer Stage 1 or 2 0.65 N/A (Dan,So and Yeoh 2006) 
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2 CHAPTER II:  GASTRIC CANCER PREVENTION  
 
Given that the efficacy of GC treatment is not satisfactory, attention has been turned to the prevention 
of GC. Prevention strategies not only work towards the reduction in mortality, but in reducing GC 
incidence. With rapid growth of the understanding on natural history of GC development, there is a 
good theoretical basis on which preventive measures should be undertaken. The factors that support 
strategy for GC prevention include: (1) The main etiologic agent, H. pylori , is known to be amenable 
to drug therapy and has a low infection rate (Fendrick et al. 1999); (2) The decade-long precancerous 
stage allows adequate time for clinical tests to detect GC early (Watabe et al. 2005); (3) Host 
susceptibility genes that carry a high risk of the disease have been identified (Figueiredo et al. 2002); 
and (4) The framework has  been clarified which proposes a multidisciplinary approach combining 
population screening with molecular biological techniques (Correa,Piazuelo and Camargo 2004). 
  
2.1 Gastric Cancer Carcinogenesis  
 
GC development is a multi-sequential and multi-factorial process which involves interactions between 
host factors, environmental factors and H. pylori infection (Figure 2-1). Correa’s model was first 
proposed to describe the natural history of intestinal adenocarcinoma (Correa 1992). At present, the 
model is widely accepted and extensively consolidated by various studies.  According to Correa’s 
model (Figure 2-1), the onset of H. pylori infection triggers the cascade of GC lesions. Chronic H. 
pylori infection exposes stomach mucosa to long-term inflammation, which is referred to as chronic 
gastritis. If untreated, stomach mucosa will lose its normal structure of glands and then atrophic 
gastritis occurs. As atrophic gastritis progresses, gastric mucosa is replaced by bowel-mucosa-like 
epithelium called intestinal metaplasia. The severe and extensive intestinal metaplasia leads to 
dysplasia and subsequently to a neoplastic lesion. The progression from H. pylori infection to gastric 
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adenocarcinoma takes years or decades as independently estimated by two models (Liu et al. 2006; 
Yeh et al. 2008).   
 
 




2.2 Chemoprevention- H. pylori Eradication 
 
2.2.1 Consequence of H. pylori infection  
Classified as a definite carcinogen for stomach cancer (de Vries,Haringsma and Kuipers 2007),  H. 
pylori infection is viewed as a necessary but insufficient causal factor for non-cardia gastric 
adenocarcinoma (Fock et al. 2008). However, GC is one of a spectrum of end diseases caused by H. 
pylori (Figure 2-2). Approximately 1% of people infected with H. pylori will finally develop GC in 
their life time (Fock et al. 2009).   
 
Figure 2-2. Clinical consequences of H. pylori infection 
 
Given the role of H. pylori infection in GC development, intuitively, eradicating this infection would 
eliminate cancer risk before precancerous lesions develop. Therefore, screening for H. pylori and 





2.2.2 Effectiveness and cost-effectiveness of H. pylori eradication  
Many studies have been conducted to examine the effect on incidence and mortality from H. pylori 
screening and eradication. Observational studies in Asia found that H. pylori eradication significantly 
reduced the GC risk for patients with peptic ulcer disease (Mabe et al. 2009; Ogura et al. 2008; Wu et 
al. 2009) who are usually associated with higher GC risk. 
 
For those with various precancerous lesions mentioned in the study by Correa et al, H. pylori 
treatment is effective in inhibiting their progression. One study reported that H. pylori eradication is 
beneficial in preventing the progression of preneoplastic lesions in the gastric mucosa (Sung et al. 
2000). In a 6-year trial in Colombia, the combination of H. pylori treatment and dietary 
supplementation with antioxidants reduced the occurrence of gastric dysplasia (Correa et al. 2000). A 
7.5-year clinical trial in China did not discover the preventive effect of H. pylori eradication for those 
already with atrophic gastritis. The researchers thus concluded that the H. pylori treatment can only be 
effective when administered early in the disease development. A  meta-analysis of five randomized 
controlled trials derived a 35% reduction of GC risk for subjects infected with H. pylori (RR=0.65, 95% 
CI: 0.42–1.01) (Ford and Moayyedi 2009).  
 
The cost-effectiveness of adopting H. pylori eradication is also demonstrated in multiple populations. 
H. pylori screening has shown to be potentially cost-effective in high-risk populations such as 
Japanese-Americans and Matsu residents in Taiwan (Lee et al. 2007; Parsonnet et al. 1996). A trial-
based economic analysis demonstrated the cost-effectiveness of population screening for H. pylori 
infection in UK (Mason et al. 2002). In Singapore, Xie et al modeled one-time H. pylori screening in 
people 30 years or older (Xie et al. 2008). The study yielded an incremental cost-effectiveness ratio of 
$25,881 per QALY (quality adjusted life year) gained which is considered cost-effective for 
Singapore. Taking into account the pros and cons of H. pylori infection eradication, the Gastric 
Cancer Consensus Conference recommended that screening for H. pylori is appropriate for high risk 
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populations. However, for low or intermediate risk populations, its effectiveness is less clear 
(Talley,Fock and Moayyedi 2008).  
 
2.2.3 Concerns about implementing population-based H. pylori screening  
Although H. pylori screening sounds like a good candidate for GC control, there is so far no 
established national program completely based on H. pylori screening and eradication. Some 
researchers suggest the use of H. pylori test and serum pepsinogen as a stratification tool. However, 
its usefulness was questioned even for high risk population (Shimoyama et al. 2012). Firstly, the long-
term efficacy of screening for H. pylori infection in the general population remains inconclusive. The 
benefit of H. pylori eradication for the subjects with precancerous lesions has not been firmly 
confirmed by randomized controlled trials (Liu et al. 2006; Wong et al. 2004). The proposed concept 
of “a point of no return” suggests that after certain point of GC development, regression to a less 
severe lesion is impossible. Secondly, a population-based program may be enormously costly and 
especially cumbersome for widespread  implementation in developing countries (Ramsey 2007). 
Thirdly, as with the treatment of other infectious pathogens, drug resistance is a critical issue (Kwon 
et al. 2003). Furthermore, asymptomatic carriers of H. pylori are less receptive to the treatment. The 
possible adverse effects of treatment will result in reluctance to comply with therapy in this group. 
Besides wasting medical resources, low compliance potentially accelerates the emergence of drug 
resistance due to premature discontinuation of treatment. Lastly, there is evidence that that H. pylori 
eradication may increase the risk of other diseases such as gastroesophageal reflux (Blaser 1999).  
 
 
2.3 Secondary Prevention – Gastric Cancer Screening or Surveillance   
 
The 5-year survival rate of early stage GC is 95% (Isobe et al. 2011), whereas a Stage 4 GC patient 
has a low chance of surviving two years after diagnosis (Hosokawa et al. 2008; Koong et al. 1996). 
The great survival advantage of early GC cases supports the hypothesis that a patient’s survival can be 
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prolonged if the disease is treated earlier. Therefore, secondary prevention focusing on early detection 
has assumed a paramount role in GC control worldwide.  
 
2.3.1 Theoretical basis for secondary prevention of gastric cancer  
Secondary prevention requires a long and identifiable preclinical phase where the abnormality can be 
examined by medical tests (Figure 2-3). A long preclinical phase is a necessary but insufficient 
condition for effective prevention. The following additional conditions need to be fulfilled: 
  
1. Appropriate interventions are available and can have greater effect on clinical outcomes if 
applied earlier  
2. All or most cases first go through a detectable preclinical phase 
3. All or most cases in a preclinical phase progress to a clinical phase without intervention.  
4. A good clinical test with high sensitivity and specificity is available and easily accessible   
 
Figure 2-3. Natural history of a disease  
 
Considering screening for GC, the above four requirements seems to be all fulfilled. This is 
demonstrated by the following evidence: (1) Correa’s model has defined a years or decades long 
preclinical phase from chronic active gastritis to neoplastic lesion (Figure 2-1) (Liu et al. 2006; Yeh et 
al. 2008), (2) As the intermediate changes have been histologically characterized, they can be 
identified by endoscopic examinations with adequate accuracy, (3) Epidemiological data shows that 
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the majority of GC cases are adenocarcinoma that went through the pathway specified by Correa’s 
model (Figure 2-1). (4) It is beyond controversy that regression of gastric precancerous lesions is 
unlikely. In summary, GC appears amenable to the secondary prevention to realize the survival 
benefit resulting from early detection.  
 
2.3.2 Effectiveness and cost-effectiveness of gastric cancer screening or surveillance 
Screening the general population has been very successful in reducing GC-specific mortality or 
improving survival time. Following the introduction of endoscopic screening, the age-adjusted GC 
mortality rates declined by 33% from 1.04 to 0.71 per 100,000 for males and by 60% from 1.54 to 
0.62 per 100,000 for females in Japan (Matsumoto et al. 2007). In a historical cohort comprising 
11,763 participants, subjects undergoing endoscopy screening had lower risk for GC death (relative 
risk = 0.35, 95% CI: 0.14-0.86) compared to those with no screening (Hosokawa et al. 2008). A 10-
year follow-up study also reported a relative risk of 0.54 (95% CI: 0.38- 0.77) for GC death for 
subjects using screening service based on a population of 41,394 persons (Miyamoto et al. 2007). The 
down-stage effect by endoscopic screening was observed in Korea and Japan (Han et al. 2003; Kubota 
et al. 2000). From a perspective of resource allocation, cost-effectiveness was indicated for 
population-based screening in a Japan study (Tsuji et al. 1991). In Singapore, a decision-analytic 
model by Dan et al. recommended the 2-yearly endoscopy screening as a cost-effective strategy to 
prevent GC death in Singaporean Chinese men aged 50-70 years (Dan, So and Yeoh 2006).  
 
Unlike screening which involves generally healthy subjects, surveillance focuses on the people with 
certain precancerous lesions and therefore at higher GC risk (de Vries,Haringsma and Kuipers 2007; 
Vannella et al. 2010). Multiple studies have provided evidence about the clinical benefit and cost-
effectiveness of endoscopic surveillance in patients with atrophic gastritis, intestinal metaplasia, 
gastric ulcer or dysplasia (Dinis-Ribeiro et al. 2007; Hassan et al. 2010; Yeh,Ho and Hur 2010; Yeh et 
al. 2010).  
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Although a few clinical interventions have been tried and tested, scientific evidences support the use 
of endoscopy as the primary tool for screening or surveillance. Clinically, the sensitivity and 
specificity of endoscopy is higher than other interventions in diagnosing and staging GC (Voutilainen 
and Juhola 2005). As a screening tool, endoscopic examination has a detection ratio of 0.87%, 
approximately three to five times higher than photoﬂuorography (Tashiro et al. 2006). It also achieved 
better cost-effectiveness in prolonging life expectancy in a Korean population (Chang et al. 2012). 
Endoscopy is also preferred over x-ray examinations as reported by a qualitative study (Choi et al. 
2009).  
 
2.3.3 Concerns about secondary prevention   
Secondary prevention is associated with a few special biases. These biases are able to compromise the 
efficacy of a screening or surveillance program and waste medical resources. When designing and 
evaluating a healthcare program aiming for early detection, it is necessary to understand and prevent 
these biases.  
  
Volunteer bias refers to the phenomenon that the participants in prevention programs tend to be 
healthier than the general population. This is a self-selection process whereby the people who are 
health-conscious tend to volunteer themselves for new medical services. The better survival of the 
screenees may solely be the fact that participants are generally healthier and have longer life 
expectancy. This bias will overestimate the survival benefit by screening.  
 
Prognostic bias is another type of selection bias related to disease progression. A patient with slowly 
progressive disease is more likely to be detected than a fast progressive one as the long preclinical 
phase provides adequate time for clinical intervention. There is data to support the idea that a long 
clinical phase is associated with a long preclinical phase and verse versa. Therefore, those captured by 
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prevention programs have longer preclinical phase and naturally have better prognosis than the cases 
normally diagnosed.  This bias also overestimates the effect of secondary prevention.  
 
Lead time bias is defined as follows. A preventive test seems to diagnose the disease earlier in disease 
history, but there is no effect on the clinical outcome. It may appear that the intervention is very 
effective, when in fact it is the earlier diagnosis that artificially prolongs the survival time. Lead time 
bias will overestimate the survival time.  
 
Over diagnosis bias has occurred when a screening program detects the silent cases which may never 
develop into a clinical case during the lifetime of a patient. It can also be caused by the eagerness to 
diagnose the target disease, which is commonly seen in the staff of a healthcare program. Those over-
diagnosed cases are considered healthy under usual medical care thus would have better prognoses. 
This bias would cause overestimation of the effect of secondary prevention. 
 
In the case of GC, few studies have been devoted to these negative aspects associated with GC 
screening or surveillance. Nevertheless some of them shed light on this area of GC prevention. Over-
diagnosis was confirmed by a study in Japan (Hamashima et al. 2006) comparing observed and 
expected GC numbers detected by cancer screening. Lead-time bias could not be ruled out in the 
longer survival of asymptomatic groups undertaking GC surveillance in another study (Cardoso et al. 
2012). Currently, there have been no large-scale studies to quantify the effect of lead time bias, 
prognostic bias, and volunteer bias and over diagnosis bias. An indirect way to estimate them is to use 




2.4 Existing National Screening Programs 
GC screening remains controversial in most countries in the Asian-pacific region. Establishing a 
public health program on a national level is more than an epidemiological issue. Practical constraints 
are involved such as capacity of health care system, public perception and availability of medical 
services. Therefore, even in Asia where most countries are categorized as high risk for GC, only two 
countries (Japan and Korea) have national GC screening programs. 
 
2.4.1 Japan  
Japan has the oldest nationwide program for GC cancer screening since 1960s (Hisamichi 1989). Any 
individual older than 40 years is eligible for a yearly screening test. During inception of the program, 
double-contrast radiography was the primary tool followed by confirmative endoscopic procedures 
upon positive finding. With expanding access to endoscopy, endoscopy becomes the most popular 
screening modality.  
  
The program in Japan has been successfully executed for half a century.  Despite the seemingly low 
compliance rate of 20% or so (Graham and Asaka 2010), its effect is encouraging as shown by 
significant reduction in mortality and morbidity (Nakashima et al. 2010; Tanaka et al. 2011). 
Nowadays, the survival experience of Japanese GC patients is the best of the world. The majority of 
GC cases (90%) are at early stage with a probability of surviving 5 years after diagnosis (Davis et al. 
2000). Japan is also interested in GC surveillance. A service structure based on hospital cancer 
registry is in the midst of completion (Graham and Asaka 2010).  
 
2.4.2 South Korea 
Korea started its National Cancer Screening program for GC in 1999. Like Japan, the Korean program 
targets people older than 40 years for a biennial screening arrangement. Two screening modalities, 
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direct upper-gastrointestinal series and endoscopy (or both), are available to be chosen according to 
the preference of participants. Given the relatively low cost and high specificity in diagnosing GC, 
endoscopy is the preferred method by the participants (Kim et al. 2011). 
  
The program has been evaluated in several studies. It was found that the proportion of early gastric 
cancer identified is significantly higher in asymptomatic individuals undertaking endoscopy screening 
than in symptomatic individuals (Kim et al. 2000; Kong et al. 2004). Economic findings from two 
recent studies have confirmed the cost-effectiveness of this program (Chang et al. 2012; Cho et al. 
2013).  
 
2.5 Summary  
 
Evidence so far supports that preventive measures are effective in reducing GC morbidity and 
mortality, despite concerns associated with both primary and secondary prevention. H. pylori 
eradication is unanimously recommended for asymptomatic persons of high risk populations. As for 
secondary prevention, consensus has yet to be reached regarding the adoption of GC screening and 
surveillance in a certain population or subgroup. However, it is clear that endoscopy is the best tool 
for such a purpose.  
 
Singapore presently does not have a nation-wide health care program for GC control. However, with 
its advanced health care system and a small population, Singapore is an ideal place for 
implementation of such a program, which in turn calls for health services research to address practical 
issues such as cost of delivering clinical service, quality of life of GC patients and finally cost-
effectiveness estimation. The population-based H. pylori infection and endoscopic screening have 
been evaluated by cost-effectiveness models (Dan, So and Yeoh 2006, Xie, Luo and Lee 2008). In 
terms of applicability of their findings, these two modeling studies are flawed by the common 
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weakness that the utility and cost were not generated based-on the target population that is Singapore 
Chinese. The surveillance strategy is yet to be evaluated or compared with recommended strategy. 
Under these circumstances, to obtain an informed choice of the optimal strategy for GC prevention 
and to facilitate implementation of an evidence-based national program in Singapore, we designed 
three studies, i.e. cost study, quality of life study and cost-effectiveness analysis.  Hopefully, these 








In the global campaign to eradicate GC, which claims over 700,000 lives every year (Jemal et al. 
2011), screening has assumed a paramount role but not without limitations (Leung et al. 2008). Even 
in Japan, the country with the highest incidence of GC, the cost-effectiveness of national GC 
screening is fading away due to the decrease in incident cases (Babazono and Hillman 1995). 
Considering the worldwide declining trend of GC incidence over the past two decades (Forman and 
Burley 2006), screening at the national level may no longer be the optimal strategy for GC eradication. 
Therefore, GC surveillance targeted at high risk subpopulations offers a complementary or alternative 
strategy given that hospital-based GC surveillance has already demonstrated its efficacy in detecting 
cases at early stages of cancer development (Dinis-Ribeiro et al. 2007; Whiting et al. 2002).  It is also 
sensible for industrialized countries with very low overall GC incidence but containing specific ethnic 
groups such as Asian immigrants among whom GC remains a major disease burden (Cho et al. 2006; 
McCracken et al. 2007).  
 
The Gastric Cancer Epidemiology Clinical and Genetic Program (GCEP) is an endoscopic 
surveillance program targeted at the Chinese population aged 50 years or above in Singapore, a 
country with an intermediate risk of GC (Fock and Ang 2010). The GCEP target population has a GC 
incidence much higher than the general population (Office 2008). Based on the preliminary 
explorations of GC endoscopic screening (Dan, So and Yeoh 2006), the GCEP was intended to inform 
the feasibility and benefit of GC surveillance as a control strategy for GC in Singapore. The GCEP 
system is established in four local general hospitals and has been running since 2004.  Its surveillance 
follow-up is incorporated into the daily work routine of the participating hospitals.   
31 
 
Cancer prevention programs are costly undertakings and are featured by many years or even decades 
of time-lag between investment and the desired outcome. This then raises an important issue of cost 
efficiency - is the program producing the service at the least cost, i.e., the lowest price per unit of 
service?  Cost efficiency is one of major determinants of actual cost-effectiveness delivered by a 
specific program (Bautista-Arredondo et al. 2008). However, to date, most cost analyses on cancer 
prevention have been cross-sectional studies which may have lead to skewed or biased cost estimates 
(Ekwueme et al. 2008; Jacobs and Baladi 1996; Smith and Barnett 2003). A survey-based top-down 
approach for data collection adopted in these studies is also prone to subjectivity (Mansley et al. 2002). 
The time-lag effect and long-term follow up associated with cancer prevention entails the 
understanding of continuous cost generation which a cross-sectional study is unable to address. 
Furthermore previous studies have not investigated the clinical cost, the patient personal cost and the 
program associated cost in the same study, and are thus limited in providing a more detailed and 
complete description of the broader economic impact of the program (Frew et al. 1999; Pavlik et al. 
1995; Robert, Brown and Garvican 2000; Subramanian et al. 2011; Urban, Anderson and Peacock 
1994).  
 
With the above considerations, a trial program such as the GCEP is the ideal vehicle to empirically 
explore and evaluate the cost efficiency of GC surveillance. Evaluating the GCEP would be very 
informative for a future cost-effectiveness analysis of GC surveillance in Singapore and has direct 
relevance to government budgeting. This will prevent incomplete information from affecting optimal 
resource allocation decisions. Thus, we designed this study with the aims of: 1) informing resource 
allocation and program budgeting in the planning of national surveillance of GC in Singapore; 2) 
providing a comprehensive cost structure for full economic evaluation of GC surveillance both locally 
and worldwide; 3) elucidating the mechanisms underlying cost generation in cancer surveillance 
programs. This information will be of value to health administrators and planners in planning similar 
programs, as well as providing a framework for health policy researchers to undertake similar studies 





3.2.1 General approach 
The GCEP is an ongoing trial surveillance program with the aim of eventually becoming a 
government-organized GC surveillance program. The most pertinent concern about establishing such 
a program is the financial impact on society by the program. Therefore, this study was conducted 
from a societal perspective, whereby the direct costs on GCEP (the healthcare provider) and the 
patients (the beneficiaries) in undertaking GCEP surveillance were measured by the bottom-up 
approach and reported as US dollars per person served (Johns, Baltussen and Hutubessy 2003).   
 
3.2.2 Service mix of the GCEP program  
According to the GCEP Protocol Version 7, once a subject was recruited, the 5-year annual follow-up 
would be customized to the individual’s risk of developing GC assessed at baseline. Those fulfilling 
any of five criteria, namely: (1) dysplasia, (2) intestinal metaplasia, (3) atrophic gastritis, (4) GC 
family history, and (5) presence of  H. pylori infection were categorized as high risk subjects and 
underwent annual oesophago-gastro-duodenoscopy (OGD) examination. All other subjects were 
classified as moderate risk and underwent OGD in Years 3 and 5 with telephone interviews or clinic 
visits in Years 1, 2, and 4. If patients were unable to be present for endoscopy, they were contacted by 
telephone for GC related symptoms. The primary outcome was the detection of early gastric cancer or 
high grade dysplasia.  
 
3.2.3 Study site, period and sample  
The GCEP consists of a decentralized service network involving the National University Hospital 
(NUH), Tan Tock Seng Hospital, Singapore General Hospital and Changi General Hospital in 
Singapore. This study used data from the NUH only, as it is a tertiary medical institution as well as 
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the program initiator. The GCEP can be divided into three distinctive phases : Start-up, Full-
Implementation and Closeout (Johns,Baltussen and Hutubessy 2003), with each phase encompassing 
different activities (Figure 3-1). Compared to the Start-up and Closeout phases, the Full 
Implementation phase (01/04/2004 – 31/12/2010) captured most of the cost-intensive activities, and 
thus closely reflected cost generation assuming the GCEP was officially implemented on a national 
scale. Therefore this study chose the first 6.5 years from 01/04/2004 to 31/10/2010 of the Full 
Implementation phase as the costing period. To ensure a minimum 2-year follow-up, we concentrated 
our analysis on the subjects recruited between 01/04/2004 and 31/03/2008 (n=749) who are still under 
follow up. Thus we studied an open cohort from which a random sample of 216 cases (29%) was 
drawn through proportionate stratified sampling by age, gender and risk profile. 
 
Figure 3-1: Phases and time frame of the GCEP 
 
3.2.4 Resource quantification and costing    
A task force funded solely by the GCEP grant was established at the NUH to exclusively operate the 
program. The GCEP as the service provider paid NUH for clinical, logistic and financial services. A 
co-payment system was also applied for clinical services whereby the GCEP provided free follow-up 
endoscopy, histology/biopsy and urease testing, and patients were liable for baseline endoscopy, 
medication, consultation and diagnostic tests prescribed at follow-ups (Figure 3-2).   
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From the NUH GCEP database, we retrospectively identified and quantified the resources consumed 
by a single subject at baseline and subsequent follow-ups by reviewing clinical casenotes and GCEP 
financial statements. Data sources of cost information included the Land Transportation Authority, 
Ministry of Manpower and the NUH financial office. The costs of each GCEP service were estimated 
by multiplying the quantities of various resources with the best-available unit cost for that resource. 
The cost components and estimation methods are summarized in Table 3-1.   
 
 
Figure 3-2. Cost Structure of the GCEP
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Table 3-1. Cost components and cost estimation of the GCEP (2004-2010) 
      
Components Items Estimate Methods Data Source 
Resource Quantification 




     Clinical  Medications Micro-costing Casenotes & NUH Name & dosage of medication Price charged by NUH 
 
Consultation Case-mix Casenotes & NUH 
Specialist consultation 
 within 3 months after OGD  Mean charge by NUH 
 
Diagnostic test Case-mix Casenotes & NUH Tests prescribed at follow-up Mean charge by NUH 
 Histology Case-mix Casenotes & NUH Biopsy during OGD Mean charge by NUH 
  Endoscopy Case-mix Casenotes & NUH Baseline & opportunistic OGD Mean charge by NUH 
         Non-clinical 
Transportation National Mean Casenotes & LTA Round trip with mean mileage  
Taxi fare based on mileage 
 by year 
Patient time Human capital approach  Casenotes & MOM One day prescribed 
Median age-gender specific  
wage by year 
  Caregiver time Human capital approach  Casenotes & MOM One day prescribed Median gross wage by year 
GCEP 
     Clinical  Endoscopy  Case-mix Casenotes & NUH Endoscopy & related procedure Fixed charge negotiated with NUH 
 
Histology Case-mix Casenotes & NUH Biopsy during OGD Fixed charge negotiated with NUH 
 Urease Case-mix Casenotes & NUH Urease test during OGD Fixed charge negotiated with NUH 
 
Doctor's time for OGD Case-mix Casenotes & NUH Mean duration for OGD  Mean salary/minute  
      Non-clinical  
  
Consumables  Direct allocation  Project record Total spending/caseload  
 GCEP staff Direct allocation  Project record Total salary/caseload  
 Overhead Direct allocation  Project record Total spending/caseload  
 
Capital  
Direct amortization  
and allocation  
Project record Annual equivalent/caseload 
  
NUH, National University Hospital; OGD, oesophago-gastro-duodenoscopy; LTA, Land Transportation Authority; MOM, Ministry of Manpower  
*





As the study was conducted in 2010, the unit costs of clinical items were based on actual hospital 
charges at that time. Although hospital charges may not truly represent the cost of the services 
provided, these were the only data available. Considering that NUH is a not-for-profit public 
healthcare institution with most charges being set based on the principle of cost recovery, the use of 
charges in this instance would be a reasonable reflection of actual costs. 
 
Non-clinical GCEP resources included capital, overhead costs, consumables and manpower, of which 
only yearly total expenditures were available. Equipment, particularly computers, was the major 
capital outlay for the GCEP. Therefore the 5-year useful life of a computer was used to calculate the 
annual equivalent of capital cost (WHO-CHOICE 2003). The overhead cost was a 20% increment of 
cash flow charged every year by the NUH to cover the office space, utilities, logistics and other 
services. The total amount of the GCEP staff salaries was used to estimate the cost of manpower. 
Unlike clinical resources, for which the consumption was recorded individually in the casenotes, non-
clinical resources were shared by all the subjects served during a given period. Thus the cost of the 
non-clinical items, the so called ‘program cost’ were directly allocated to each subject 
(Johns,Baltussen and Hutubessy 2003; Subramanian et al. 2011). Given that the telephone interview, 
clinic visit and OGD examination consumed different amounts of time and non-clinical resources, 
they were assigned as ‘1’, ‘2’ and ‘3’ unit weight respectively to reflect the relative utilization of these 
resources. The program cost was then assigned to each subject based on their individual weights. 
Caregiver time refers to when patients were accompanied by a person other than a nurse to the NUH.   
 
3.2.5 Outcomes 
All individual items were categorized into four components, from which primary outcomes originated 
for this study (Table 3-1). These outcomes comprised four cost indices that were informative and 
essential to future cost-effectiveness analysis and program budgeting (Drummond 2005). These 
indices (expressed as US$ per capita) were: 1) Overall Cost (which includes Patient Clinical,  Patient 
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Non-clinical, GCEP Clinical and GCEP Non-clinical) quantifying the overall resource consumption; 2) 
Clinical Cost (which includes Patient Clinical and GCEP Clinical) quantifying the consumption of 
clinical resources; 3) GCEP Cost (which includes GCEP Clinical and GCEP Non-clinical) quantifying 
the economic burden on the health care provider – the GCEP; and 4) Personal Cost (which includes 
Patient Clinical and Patient Non-clinical) quantifying the cost for a subject to receive GCEP services. 
These cost indices were presented in 2004 US dollars with 3% discount rate (Weinstein et al. 1996).  
 
3.2.6 Statistical analysis 
All four cost indices were computed for each subject in every financial year within the costing period. 
The Student’s t-test, Chi-Square test and survival analysis were used to compare continuous variables, 
categorical variables and rates between the sample and the cohort respectively. Since economic data 
are generally right-skewed and right-censored (Desgagne et al. 1998), this study used the semi-
parametric bootstrapping method (n=1000) to calculate standard errors. The data in each year of the 
same subject was correlated across follow-up time. To adjust for this within-subject correlation, 
multivariate Generalized Estimation Equation (GEE) was used to model the data and to quantify and 
test the potential temporal trends in outcome indices. Due to the co-payment system, the temporal 
trends of the GCEP Cost and Personal Cost would be biased if baseline OGD was included in the 
analysis. Hence, we excluded the baseline data from the analysis of these two indices. As year 2004 
had only baseline OGDs, the data from this year was not presented in the results of the GCEP Cost 
and Personal Cost.  Statistical analyses were performed using SPSS (version 19; SPSS, Inc, Chicago, 
IL), STATA version 10 (Stata Corporation, TX) and Microsoft Excel 2007 (Microsoft, Redmond, 




3.3 Results  
 
The workload of GCEP has been increasing throughout the costing period (Table 3-2).   
Table 3-2. Yearly patient volume of GCEP (2004 to 2010) 
Year 2004 2005 2006 2007 2008 2009 2010* Total 
New recruitments 121 164 121 305 343 179 104 1337 
Follow-ups 5 141 326 475 762 1049 415 3173 
Patients Served  126 305 447 780 1105 1228 519 4510 
* 
 Costing  period is up to 31/10/2010 
 
 
The study sample adequately represented the NUH GCEP cohort (Table 3-3). With the exception of 
the follow-up time, which was 2.5 months longer for the study sample (p=0.03), the sample and 
cohort were homogenous with respect to demographics, patient outcome and event rates with 
insignificant p values.   
Table 3-3. Characteristics of the study cohort and sample  









60.13  (7.32) 7.32  (60.23) 0.86
†
 
Age group 50-59 years 426  (56.88)  121 (56.02) 
 
 
≥60 years 323  (43.12)  95 (43.98) 0.88‡ 
Gender Male 401  (53.54) 123 (56.94) 
 
Female 348  (46.46) 93 (43.06) 0.39
‡
 
Risk profile Moderate 211  (28.17)  59 (27.31) 
 







3.34  (1.28) 3.55 (1.22) 0.03
 †
 
Outcome EGC 6  (0.8)   1 (0.46) 
 
Death 7  (0.93)  2 (0.93) 
 
Drop-out 49  (6.54)  8 (3.70) 
 





















1959  (1481, 2592) 1049  (524, 2097) 0.83
 §
 




Values are the mean (SD) for continuous variables and n (%) for categorical variables. Rates are reported 










 Fisher’s exact test based on rate difference  
║ 
Unit of rates is 1/100,000 per year.  
 
The cost efficiency of the GCEP improved over time. As shown in 3, the monetary value of all four 
cost indices declined throughout the 6.5-year costing period. Despite variations over time, the 
downward trends of the cost indices were apparent from the onset of the GCEP. The mean Overall 
Cost of serving one subject steadily declined by 42.3% from US$1025 in 2004 to US$591 in 2010. 
The Clinical Cost, GCEP Cost, and Personal Cost also declined by 54.1%, 30%  and 25.7% over this 
period respectively.  The difference in magnitude of cost reduction is the result of the cost 
components constituting each index.   
 
Figure 3-3. Temporal trends (2004-2010) of cost indices for the whole sample. 
Individual points represent the means of cost indices in each follow-up year 
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As age and gender are critical for defining the target population for GC surveillance, the downward 
trends of the cost indices were further investigated in the age (50-59 year vs. ≥60 year) and gender 
(male vs. female) subgroups. In Figures 3-4 and 3-5, cost indices experienced slow and steady decline 
in all four demographic subgroups as they did in whole sample. Across the four groups, the Overall 
Cost dropped by between 40% and 47%. The Clinical Cost dropped by 52.1% to 58.4% and the 
GCEP Cost dropped by between 23% and 39%.  The Personal Cost had the least percentage drop of 
3.5% for the age group 50-59 years, and the biggest drop of 43% for the age group ≥60 years. The 
downward trends were demonstrated to be robust to age and gender. Furthermore, Figures 3-4 and 3-5 
illustrated that the curves representing subgroups based on age or gender overlapped on large part and 
were almost identical, suggesting that resource consumption was not associated with a subject’s age 
or gender.  
 
  
Figure 3-4. Temporal trends (2004-2010) of cost indices for the age subgroups. 





Figure 3-5. Temporal trends (2004-2010) of cost indices for the gender subgroups. 
Individual points represent the means of cost indices in each follow-up year 
As per the GCEP protocol, risk assessment at baseline determines the number of OGD which a GCEP 
subject will take during follow-up and is an important modifiable factor for resource allocation. As 
expected, the risk profile had a big impact on cost indices for the two risk groups. In Figure 3-6, the 
cost curves for the high risk group ran above those of the moderate risk group for all cost indices, 
illustrating that the high risk subjects consumed more resources than the moderate risk subjects. The 
Overall Cost, Clinical Cost, GCEP Cost and Personal Cost of the moderate risk group accounted for 
77%, 68.1%, 60% and 65.1% of the high risk group respectively.   
 
Risk profile also affected the downward trend pattern. The temporal trends were not universally 
downward for three pairs of risk groups or for all cost indices (6). The Overall Cost and Clinical Cost 
retained their downward trends for both the high risk and moderate risk groups. However, the GCEP 
Cost and Personal Cost differed dependent on the risk profile.  On average, the GCEP Cost to serve 
one subject at the high risk dropped by 38.2%, while it increased by 62.6% for a moderate risk subject 
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over the costing period. Similarly, the Personal Cost paid by a single high risk subject dropped by 
36.5%, while it increased by 76.1% from US$46 in 2005 to US$81 in 2010 in moderate risk subjects.       
 
Figure 3-6. Temporal trends (2004-2010) of cost indices for the risk subgroups. 
Individual points represent the means of cost indices in each follow-up year 
The GEE models fitting the temporal trends of cost indices and the comparison of the trends between 
the three pairs of subgroups of age, gender and risk profile are presented in Table 3-4. Twenty six out 
of 28 GEE models in Table 3-4A confirmed the downward trends as shown in Figures 3-3 to Figure 
3-6, with highly significant p values and negative annual change in monetary values. Only two GEE 
models fitting the GCEP Cost and Personal Cost for the moderate risk group suggested a cost increase 
over the follow-up period. Comparative analysis of the cost trends in the subgroups revealed how 
other factors affected resource allocation. Significant results were only found when more resources 
were allocated to the high risk group than to the moderate risk group (Table 3-4B). There were no 
significant differences in annual expenses within age or gender subgroups.  
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Table 3-4. GEE models fitting temporal trends of cost indices and comparison of subgroup trends.   












 Mean 95% CI
‡
 P  Mean 95% CI
‡
 P 
A: Temporal trends                            
Whole Sample
*
   -106 (-117, -95) <0.001 -40 (-46, -34) <0.001 -48 (-63, -34) <0.001 -9 (-12, -4) <0.001 
    Age (year)
 *
 50-59  -109 (-124, -94) <0.001 -41 (-49, -33) <0.001 -40 (-60, -19)   <0.001 -7 (-12, -1) 0.01 
  >=60  -102 (-117, -87) <0.001 -37 (-47, -28) <0.001 -59 (-78, -39) <0.001 -10 (-15, -5) <0.001 
   Gender
*
 Male -101 (-115, -87) <0.001 -37 (-45, -29) <0.001 -44 (-62, -26) <0.001 -7 (-12, -1) 0.009 
  Female -112 (-131, -93) <0.001 -43 (-53, -34) <0.001 -54 (-77, -32) <0.001 -10 (-15, -4) 0.001 
  Risk Profile
*
 High -112 (-123, -100) <0.001 -43 (-49, -36) <0.001 -73 (-87, -60) <0.001 -13 (-17, -10) <0.001 
  Moderate -46 (-61, -32) <0.001 -18 (-28, -7) 0.001 26 (3, 49) 0.027 5 (-3, 14) 0.212 
B: Comparisons between subgroups                         
    >=60 year vs. 50-59
†
   21 (-23, 65) 0.36 17 (-5, 40) 0.127 34 (-17, 84) 0.188 4 (-11, 18) 0.634 
    Male vs. Female
†
   10 (-35, 54) 0.675 1 (-21, 22) 0.965 15 (-34, 65) 0.536 7 (-8, 21) 0.382 
    High vs. Moderate
†
   192 (155, 228) <0.001 87 (68, 104) <0.001 226 (190, 263) <0.001 39 (26, 52) <0.001 
Abbreviations: C.I., confidence interval  
 
*
Means decrement/increment across costing period.  
†






To the best of our knowledge, studies about continuous cost generation of cancer prevention programs 
have not been previously reported despite that many studies have acknowledged the limitations of 
cross-sectional cost estimates. Our study attempts to fill this gap. The gradual and continuous decline 
of cost indices in our study strongly indicated the ever-improving cost efficiency of endoscopic 
surveillance for GC through the GCEP during the observation period. This study as a free standing 
cost analysis, despite its inability to compute the cost-effectiveness ratio, provided important 
empirical evidence for program management and ultimately for value-for-money decision making. 
Cost studies of long-term GC surveillance have long been anticipated worldwide given that research 
already illustrated the benefit of GC surveillance (Filomena et al. 2011; Whiting et al. 2002). 
Exploring the mechanisms underlying our results would be of universal interest to GC researchers.   
 
Economy of scale is considered the main reason for the cost reduction, especially for the Overall Cost 
and the GCEP Cost (Mansley et al. 2002; Subramanian et al. 2011). Previous studies have shown that 
as screening volume increased, the average cost borne by the health care provider to serve one subject 
decreased, thereby approximating an inverse relationship (Breen and Brown 1994). The GCEP 
experienced a 7-fold increase of patient volume from 175 in 2004 to 1223 in 2009. Consequently the 
average cost decreased because fixed costs spread out horizontally across the number of subjects 
served every year and vertically along the implementation time. Correlation analysis showed a 
negative correlation coefficient between workload and Overall Cost and GCEP Cost, with the former 
achieving statistical significance (r= -0.821, p=0.023).  
 
More efficient utilization of the resources within the GCEP system was another factor driving the 
GCEP Cost down. It is well known that public health programs improve operational efficiency 
through self-learning (Smith and Barnett 2003), which in return leads to decreased costs borne by the 
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service provider. Having been in operation for seven years and with quality assurance protocols in 
place, the GCEP could optimize work-flow processes by shortening waiting times, avoiding 
repetitions and enhancing service awareness in team members (Sickles et al. 1986). Although specific 
parameters were not set to gauge its work-flow processes, it was fair to assume that the self-learning 
mechanism took effect, especially in the inception of the Full Implementation phase which was the 
costing period of our study.   
 
The decline in Clinical Cost indicated that subjects consumed less of the clinical services, which 
consist of follow-up OGD, specialist consultations, diagnostic tests and medications (Table 3-1). This 
is most likely due to a reduced demand for clinical services in later follow-ups when the subjects were 
experiencing fewer symptoms as a result of surveillance and associated treatment. Our findings were 
consistent with a cost study of a colorectal cancer screening program which showed that repeated 
screenings cost less than initial screenings because of the lower prevalence of disease in the 
rescreening group as opposed to first-time participants (Grazzini et al. 2008). Congruent with the 
previous observation, the Personal Cost also decreased as patients paid less for clinical services. 
 
A further reason for the Personal Cost reduction was the declining price of patient time estimated by 
the human capital approach (Ekwueme et al. 2008), whereby the opportunity cost of taking one day 
off work for an OGD or clinic visit was measured as a single day’s salary. In Singapore, there was a 
large decrease in salary from the age group 50-59 years to the age group 60 years or above (Ministry 
of Manpower 2010). As one of the GCEP inclusion criteria was being age 50 years old or above, we 
noted that during the observation period, 42 (19.4%) subjects underwent the age change from 50-59 
years old to 60 years old and above.   
 
Subgroup analysis was conducted to explore the cost generation in subgroups categorized by age and 
gender, which are relevant to the diagnostic yield of a screening program (Denis et al. 2007; Nakama 
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et al. 2001). Similar to the observation for the whole sample, both gender subgroups experienced 
significant annual decreases with bigger decrements in females for all the four cost indices (Table 3-3). 
As for impact of age, compared with subjects 60 years or older, subjects between 50 and 59 years had 
a larger decrement in Overall Cost and Clinical Cost, US$109 vs. US$102 and US$41 vs. US$37 
respectively, and a smaller decrement in the GCEP Cost and Personal Cost, US$40 vs. US$59 and 
US$7 vs. US$10 respectively (Table 3-3). However, comparing the average costs of the subgroups for 
either variable failed to reveal significant differences, as illustrated by the overlapping curves in 
Figures III-4 and III-5. The cost efficiency in subgroups as described above was of great significance 
in advising resource distribution among these subgroups and in computing population specific cost-
effectiveness ratios subsequently.   
 
As the cost-effectiveness of screening is sensitive to disease incidence in target populations (Dan, So 
and Yeoh 2006; Di Giulio et al. 2009), the GCEP classified subjects into high and moderate risk of 
GC which subsequently determined the frequency of surveillance OGD. The temporal trends of cost 
indices were statistically different between high and moderate risk groups (6 and Table 3-3). The 
Overall Cost and the Clinical Cost for the high risk group had annual decrements 2.4 times lower than 
those for the moderate risk group. The GCEP Cost and Personal Cost showed a downward trend in the 
high risk group, while they both increased over time in the moderate group. The cost difference 
between high and moderate risk groups was arbitrary as OGD frequencies were decided beforehand, 
yet it has implications for funding and for evaluating the cost-effectiveness of a specific population.   
 
Compared to other published cost-analyses of cancer screening programs, our study was unique in 
four ways, in that we: 1) analyzed long-term continuous cost generation; 2) collected individual-level 
data; 3) identified and quantified all possible resources; and 4) studied multiple indices 
simultaneously. The advantages of these are discussed as follows. 
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Given that long-term or life-long follow-up is required in a cancer surveillance program we studied a 
prospective cohort, the GCEP, with 6.5-year follow-up data and reported on the temporal trends of 
cost indices, in addition to the point estimates which are the sole outcomes in cross-sectional studies 
(Ekwueme et al. 2008; Subramanian et al. 2011). There is a high likelihood that point estimates are 
skewed or biased depending on the period chosen in a specific study (Jacobs and Baladi 1996; 
Subramanian et al. 2008). Program activities and patient volume varv greatly from year to year 
resulting in inflated/deflated point estimates (Ekwueme et al. 2008; Whynes and Nottingham 2004). 
Our study, rather than overestimating/underestimating the cost values, reported on the temporal 
variation of costs that can be used to predict the variability and the evolution of the cost - two aspects 
crucial for program budgeting.   
 
Regarding the quality of data, our study collected individual-level data based on the NUH GCEP 
database. The quality of our data afforded statistical advantages over aggregate data analyzed in other 
studies (Ekwueme et al. 2008; Legood et al. 2005). Our individual-level data captured person-to-
person and year-to-year variations which allowed us to estimate the means and confidence intervals 
from actual distributions and to apply GEE models, thereby enhancing the validity and reliability of 
our results.  
 
In addition, we used patient casenotes and GCEP financial statements to identify clinical and non-
clinical items directly associated with program operation. A bottom-up approach was adopted to 
quantify resources consumed and to estimate their monetary value (Johns,Baltussen and Hutubessy 
2003; Walker 2001), thereby avoiding subjectivity or recall bias when data  is collected through a 
survey-based top-down approach (Smith and Barnett 2003), and ensuing high accuracy and 




A major contribution of our study was that we simultaneously investigated multiple cost indices, each 
of which has been a focus in previous separate studies (Ekwueme et al. 2008; Ekwueme et al. 2008; 
Mansley et al. 2002; Secker-Walker et al. 1999). To our knowledge, no study has investigated these 
indices simultaneously in a single study thereby overlooking the fact that these costs accrued 
concurrently. Complete and accurate cost data are crucial to both an economic evaluation and 
program planning. Economic evaluations tend to underestimate the cost because of poor 
representation of personal costs and program costs (van Gils et al. 2010). The personal cost represents 
the financial commitment of a subject to participate in screening (Frew et al. 1999; Secker-Walker et 
al. 1999), so it is associated with subject compliance and program effectiveness (Heitman et al. 2008; 
Zapka et al. 1989). Our study found that patients paid at the most 18.2% of what was borne by the 
service provider (the GCEP) (Figure 3-3), suggesting that co-payment is a viable arrangement. 
Program cost measures the expenditure on non-clinical activities and represent the internal resource 
allocation within programs. A cost analysis of a colon cancer screening program demonstrated that 
non-clinical activities consumed more than 50% of the total budget (Subramanian et al. 2011), 
exceeding the US federal standard of 40% (Centers for Disease Control and Prevention 2005).  In our 
study, the Clinical Cost accounted for only 17.35% to 35.76% of the Overall Cost, (i.e., the non-
clinical cost ranged between 64.24% and 82.65%) (3). Although this study took a societal perspective 
and applied a narrower definition of clinical service, as an organized surveillance program in a small 
country such as Singapore, a high proportion of non-clinical expenditure appealed to the more 
efficient internal resource allocation.  
 
We acknowledge several limitations with our study. As a pure cost analysis, this study is inherently 
unable to inform the value-for-money decision which is of utmost importance. In addition, service 
underutilization which is negatively associated with program effectiveness, cannot be ruled out as a 
mechanism driving down the clinical and personal cost in our study. The co-payment system whereby 
patients commit to a certain amount of money could impede some patients from using GCEP services, 
especially those from low-income families (Heitman et al. 2008; McAlearney et al. 2007; Urban, 
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Anderson and Peacock 1994). Removal of patient costs has been demonstrated to increase the 
screening compliance (Baron et al. 2008). Retrospective data collection in the current study cannot 
accurately match the cost with the specific clinical or administrative activities. Therefore, we could 
not identify the area of inefficiency. As for the Personal Cost, we may have omitted some elements 
which could only be retrieved through personal interview. Furthermore, caution is needed to 
extrapolate the downward trends beyond the observation period, because all the factors accounting for 
the cost reduction have limits (Subramanian et al. 2011). Nonetheless, our results confirmed 
continuous cost decrements in the early phase after full implementation. However, data seemed to 
indicate that the descending momentum stopped in 2009 (Figure 3-3, Figure 3-4, Figure 3-5 and 
Figure 3-6). The ideal situation is that a program achieves its optimal cost efficiency and functions on 
its minimum average cost curve (Mansley et al. 2002). A measure of the success of a program is how 
soon this point is reached, however this was not captured in our study.            
 
3.5 Conclusion  
 
Our study highlighted the importance of assessing the cost efficiency of a pilot project for future 
economic evaluation and government planning. The downward trends in cost indices and the factors 
contributing towards them offers valuable insights for future program budgeting and policy making. It 
is crucial for health administrators and planners to identify these factors and to further maximize their 
effect on cost efficiency in order for their programs to succeed. Furthermore, our study illustrated the 
distinct pattern of resource consumption and its temporal variation in individual subgroups classified 
by variables defining the target population. These findings call for accurate classification of the target 
population and for the computation of a population specific cost-effectiveness ratio.  
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4 CHAPTER IV: QUALITY OF LIFE OF PATIENTS WITH GASTRIC CANCER 
 
4.1 Introduction  
 
Quality of life (QoL) has been increasingly recognized as an important outcome for cancer therapy 
(Conroy,Uwer and Deblock 2007). QoL assessment has special clinical significance in the 
management of patients with GC, as the malignancy in a large proportion of GC patients is manifested 
in the form of ascites or lymphangitis carcinomatosa, thus rendering the ordinary response criteria 
such as tumor size less informative. A valid and reliable instrument is critical to obtain QoL data of 
both clinical and public health relevance (Holzner et al. 2001). 
 
As most QoL questionnaires are developed in western countries, validating these questionnaires for 
use in other target populations becomes a necessary task for health outcomes researchers and clinical 
physicians alike. The Functional Assessment of Chronic Illness Therapy (FACIT) is a collection of 
questionnaires developed primarily for the QoL measurement for various cancers. FACIT has been 
established internationally as one of the reliable and valid QoL measurement systems in clinical 
oncology (Webster,Cella and Yost 2003). The core module of FACIT, the Functional Assessment of 
Cancer Therapy- General (FACT-G), has advantage over other cancer-generic QoL instruments in 
sample size requirements (Cheung et al. 2005).  Simply adding cancer specific symptom items for a 
particular organ to FACT-G derives an organ-specific cancer QoL instrument, such as those for colon, 
lung and breast cancer (Webster, Cella and Yost 2003). These instruments have been validated and 
widely used in different populations internationally (Saitoh et al. 2007; Tong et al. 2009; Uwer et al. 
2011).  
 
However, the GC specific module based on FACT-G, the Functional Assessment of Cancer Therapy-
Gastric (FACT-Ga) (S. L. Eremenco 2004), has not been sufficiently validated. There are only two 
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recent publications validating FACT-Ga in Western populations (Debb et al. 2011; Garland et al. 
2011), however there is no data for Chinese populations, which have a higher GC incidence and 
mortality (Ang et al. 2005; Bertuccio et al. 2009) observed not only in mainland China, but also ethnic 
Chinese communities residing in other countries such as Australia (Anikeeva et al. 2012; Zhang, 
MacLennan and Berry 1984). 
 
Previous attempts have been made to validate FACT-G for its use in cancer patients of Chinese 
ethnicity (Cheung et al. 2009; Cheung et al. 2004; Yu et al. 2000) but GC was not covered explicitly 
in these studies. Therefore, how well the FACT-G or FACT-Ga performs in measuring the QoL of 
Chinese patients with GC remains unknown. In Singapore, the Chinese constitute 75% of  the entire 
population and carries an intermediate risk of GC in general and a high risk in males aged 50 years  or 
older (Fock and Ang 2010). Furthermore, the multilingual culture in Singapore enables the validation 
of both the English and Chinese versions of the instrument and its use in a broader population base. 
As such, we designed this study to examine the psychometric properties of FACT-Ga with a sample 
of GC patients from the Singapore Chinese population. Our aim was to validate FACT-Ga as a GC 
specific QoL instrument for use in Chinese populations. Empirical evidence of the reliability, 
construct validity and sensitivity to patients’ clinical status of FACT-Ga is reported.  
 
4.2 Method and Materials  
 
4.2.1 Study sample     
4.2.1.1 Sample size estimation 
 
Guidelines of sample size requirement specifically for validation study are not available in the 
literature. For the FACIT questionnaires, a sample of 50 cancer patients are considered acceptable and 
adequate (Webster,Cella and Yost 2003).  
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4.2.1.2 Requirement of clinical heterogeneity 
 
In order for an instrument to be used in various patient subgroups, questionnaire validation requires a 
sample of high clinical heterogeneity (Peter M. Fayers 2007), that is, the sample should be 
representative of all clinical cases commonly seen in clinical practice. It does not necessarily mean a 
complete list of clinical cases. However, for the factors of important clinical relevance, their variants 
should be present in the sample. The sufficiency of sample heterogeneity refers to the maximum 
coverage of clinical characteristics. In the case of gastric cancer, these factors refer to purposes of 
treatment (Sadighi et al. 2009) and clinical stages (Huang et al. 2007).  
 
4.2.1.3 Sampling protocol  
 
The study was conducted between November 2010 and October 2011 at NUH, Singapore. Patients 
from the General Surgery Clinic and the Cancer Institute of Singapore at NUH were recruited using 
the following inclusion criteria, 1) Chinese ethnicity, 2) age 45 years or older, 3) histologically 
confirmed GC, 4) at least two weeks after operation, 5) no evidence of other concurrent severe 
medical conditions, and 6) able to complete the questionnaires independently (Figure 4 1). The study 
was approved by the Domain Specific Review Board of NUH. All participants provided written 




Figure 4-1. Sampling Frame of quality of life study 
 
4.2.1.4 Patient recruitment  
 
During the one year sampling period, 80 GC patients were approached. Among them, 75 agreed to 
participate in the present study, giving rise to a response rate of 94%. Three participants were illiterate 
and two participants had severe comorbidities. A further three patients suffered substantial missing 
information in their clinical data. So these eight patients were excluded. Finally, a sample of totally 67 





Figure 4-2. Subject recruitment process 
 
4.2.2 Quality of life instruments    
In the presence of the interviewer, patients independently completed two questionnaires, the FACT-
Ga (Version 4) and the 3-level European Quality of Life-5 Dimensions (EQ-5D) in English or 
Chinese in accordance with their language preference. The order of the two instruments was 
randomized to rule out order effects (Cheung et al. 2004).  
 
FACT-Ga evaluates the participant’s life over the past seven days and consists of two parts: (A) the 
core module FACT-G which comprises four general subscales, namely physical well-being (PWB), 
social well-being (SWB), emotional well-being (EWB) and functional well-being (FWB); and (B) a 
19-item gastric cancer subscale (GCS) surveying GC symptoms and adverse effects associated with 
GC treatment. The FACT-Ga items are rated on a 5-point Likert scale. Summation of item scores 
produces scores for the PWB, SWB, EWB, FWB and GCS subscales. The aggregate of the PWB, 
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SWB, EWB and FWB scores is the FACT-G total score. The FACT-Ga total score is the sum of the 
FACT-G total score and GCS subscale scores. Higher scores indicate a better quality of life.  
 
Figure 4-3. Factor structure of FACT-G  
 
   
Figure 4-4. Factor structure of FACT-Ga   
 
We chose EQ-5D questionnaire as the generic QoL instrument to validate FACT-Ga. Developed in 
the principle of time-trade-off, EQ-5D is a well-established instrument producing reliable QoL 
measures. The EQ-5D scores can be used as utility weight for calculation of quality adjusted life years 
in cost-effectiveness analysis. For the EQ-5D, participants were required to rate their QoL on the day 
of interview. The EQ-5D questionnaire measures five domains of the patient’s life, i.e. Mobility, Self-
Care, Usual Activities, Pain/Discomfort and Anxiety/Depression. The domain scores are used to 
compute a utility anchored between 0 (death) and 1 (full health) (Dolan and Gudex 1995). Similar to 
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FACT-Ga scores, higher EQ-5D utility indicates a better quality of life. The utility weight for each 
domain is presented in the Table 4-1. The EQ-5D utility is calculated by the formula below. 
EQ-5D Utility = 1 - 0.081 – 0.269 (if any domain is rated at level 3) 
- (βM*Mobility + βS*Self-care + βU*Usual Activity + βP*Pain/Discomfort + βA*Anxiety/Depression) 
 
Table 4-1. Utility weights for EQ-5D domains   
 















  0 0 0 0 0 
Level 2  0.069 0.104 0.036 0.123 0.071 
Level 3 0.269 0.314 0.214 0.094 0.386 0.236 
 
4.2.3 Statistical analysis  
The English and Chinese questionnaires were pooled for the analysis as the measurement equivalence 
between two language versions of EQ-5D and FACT-G has been previously confirmed in 
Singaporean Chinese (Cheung et al. 2004; Gao et al. 2009).  
 
As participants were given the option of not answering the seventh item of the SWB subscale, GS7 
(“I am satisfied with my sex life”), 32 (48%) participants did not respond to this item. The SWB 
subscale scores for these subjects were prorated following the FACIT Administration and Scoring 
Guidelines (Cella 1997). Ceiling effect for a scale is defined as percentage of subjects rating the 
highest scores. A percentage above 15% is considered unacceptable (Terwee et al. 2007). 
 
Reliability was quantified as internal consistency by using the Cronbach’s α. An alpha value equal to 
or greater than 0.70 was considered satisfactory (Nunnally 1978). The sensitivity to clinical severity 
was tested in relation to the clinical variables, Treatment Intent (curative vs. palliative) and Clinical 
Stage (6
th
 American Joint Committee on Cancer (AJCC) Stage 0,1,2,3 vs. AJCC Stage 4), using the 
effect size and the significance level of the Student’s t-test.   
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Correlation analysis was performed to assess the construct validities of FACT-Ga. Convergent 
validity is supported if an item has a correlation coefficient of 0.4 or higher with its own scale (Peter 
M. Fayers 2007). Discriminant validity is supported if the correlation coefficient with its own scale is 
higher than that with any other scales.  
 
The convergent and discriminant validities were further evaluated using the multitrait-multimethod 
(MTMM) approach for incomplete design, which explored all inter-scale correlations among the EQ-
5D domains and FACT-Ga subscales (Trochim 2006). These correlations were quantified as 
Spearman correlation coefficients for rank data considering that three levels of each EQ-5D domain 
are not equally spaced (Salaffi et al. 2011; van Stel and Buskens 2006). Although it has been proposed 
to combine Level 2 and Level 3 as one category of “with problem” in correlation analysis with item 
levels (Luo et al. 2003), this study did not adopt this practice for the sake of loss of information.  
 
As EQ-5D is a generic QoL instrument and FACT-Ga is a GC specific QoL instrument, there was no 
one-to-one correspondence of the QoL constructs across the two questionnaires.  Based on content 
validity of two questionnaires, we hypothesized theoretically that the FACT-Ga PWB, EWB and 
FWB subscales corresponded to the EQ-5D Pain/Discomfort, Anxiety/Depression and Usual Activity 
domains respectively, whilst the FACT-Ga GCS subscale corresponded to the EQ-5D 
Pain/Discomfort domain. The correlations between these QoL construct pairs are the monotrait-
multimethod correlations in the MTMM correlation matrix. As an incomplete design was adopted, 
these correlations would not line up as a validity diagonal. The remaining cross-instrument inter-scale 
correlations are termed multitrait-multimethod correlations. Both convergent validity and discriminant 
validity are supported if the strengths of the monotrait-multimethod correlations are stronger than the 
multitrait-multimethod correlations as expected a priori. The statistical software package SPSS v17 
(SPSS Inc, Chicago, Illinois) was used to perform all analyses. A p-value less than 0.05 was 





The demographic and clinical characteristics of the sample are summarized in Table 4-2. The mean 
age of the participants was 67 years and the average survival time was 2.13 years after diagnosis. 
Approximately 75% of participants chose the Chinese version of the questionnaires. Our sample has a 
representative range of clinical cases, including patients diagnosed with AJCC stage 0 to stage 4, 
those with or without previous surgery, metastases, and a history of chemo/radiotherapy. The majority 
of these patients received treatment in hospital with a curative (71.6 %) rather than a palliative intent.   




Age (years)  67.38 + 11.87 
Survival time (years)  2.13 + 2.45 
Gender Male 43 (64.18) 
 Female 24 (35.82) 
Language Chinese 50 (74.63) 
 English 17 (25.37) 
AJCC stage (6
th
 edition) Stage 0 3 (4.48) 
 Stage 1 19 (28.35) 
 Stage 2 14 (20.90) 
 Stage 3 13 (19.40) 
 Stage 4 18 (26.87) 
Metastasis No  54 (80.59) 
 Yes 13 (19.41) 
Treatment Intent Curative 48 (71.60) 
 Palliative 19 (28.40) 
History of surgery Total gastrectomy 12 (17.91) 
 Subtotal gastrectomy  37 (55.22) 
 Surgical procedure  4 (5.97) 
 No surgery 14 (20.90) 
History of chemo/radiotherapy No  44 (65.67) 
  Yes 23 (34.33) 
*




4.3.1 Ceiling effect and the reliability index  
The distributions of the FACT-Ga scores and EQ-5D utility, the ceiling effect and the reliability index 
are presented in Table 4-3. Each score had a slightly left-skewed distribution as the medians were 
greater than the means. A floor effect was not observed but a ceiling effect was present for all scorers 
with notable values for the PWB (26.87%), SWB (16.42%) , EWB (16.42%) subscales and the EQ-
5D utility (47.76%) (McHorney and Tarlov 1995). Cronbach’s α values showed excellent reliability 
for both FACT-Ga and EQ-5D as only the EWB subscale had a value below 0.7 (Nunnally 1978).   
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 range  
Observed  
Range  





Cronbach’s α  
 Item-Scale  
Correlation (range) 
No of success†/total (%) 
PWB 7 (0 - 28) (5 - 28) 26 24.31 + 4.08   26.87 0.85  0.47-0.73 7/7 (100) 
SWB
†
 7 (0 - 28) (8 - 28) 23 21.51 + 5.45   16.42 0.82  0.44-0.68 7/7 (100) 
EWB 6 (0 - 24) (10 - 24) 21 20.08 + 3.40   16.42 0.62  0.08-0.56 4/6 (67) 
FWB 7 (0 - 28) (5 - 28) 21 19.29 + 6.58   10.45 0.89  0.47-0.81 7/7 (100) 
FACT-G 27 (0 - 108) (47 - 108) 86 85.19 + 14.55   2.99 0.89  0.08-0.81 25/27 (93) 
GCS 19 (0 - 76) (27 - 76) 63 59.91 + 12.18   4.48 0.90  0.25-0.78 15/19 (79) 
FACT-Ga 46 (0 - 184) (74 - 184) 149 144.72 + 24.51   2.99 0.93  0.08-0.81 40/46 (87) 
EQ-5D 5 (-0.59 - 1) (-0.06 - 1) 0.88 0.80 + 0.28   47.76 0.81    
*Ceiling effect: Percentage of subjects who reached the highest score of the scale.  
†Cronbach’s α was computed based on 6 items exclusive of GS7 
 
Table 4-4. Sensitivity of FACT-Ga scores and EQ-5D utility to clinical severity  









Size P  
Early stage 
 (n=49) 




 Mean (SD) Mean (SD)  Mean (SD) Mean (SD) 
PWB 24.81 (3.90)  23.05 (4.36)  0.45 0.112  24.65 (4.01) 23.39 (4.24) 0.32 0.264 
SWB 21.33 (5.86)  21.94 (4.34)  -0.10 0.686  20.94 (5.94) 23.06 (3.48) -0.36 0.079 
EWB 20.63 (2.95)  18.71 (4.11)  0.65 0.036  20.37 (2.97) 19.3 (4.38) 0.36 0.256 
FWB 20.61 (6.26)  15.95 (6.31)  0.74 0.008  19.94 (6.52) 17.5 (6.57) 0.37 0.180 
GCS 61.43 (11.59)  56.08 (13.12)  0.46 0.106  61.8 (10.95) 54.77 (14.12) 0.64 0.035 
FACT-G 87.39 (13.77)  79.64 (15.34)  0.56 0.049  85.91 (14.57) 83.24 (14.74) 0.18 0.511 
FACT-Ga 148.5 (22.76)  135.18 (6.77)  0.59 0.044  147.37 (22.99) 137.52 ( 27.67) 0.43 0.146 
EQ-5D 0.86 (0.24)  0.65 (0.33)  0.89 0.016  0.84 (0.25) 0.68 (0.33) 0.66 0.031 






 In the analysis of sensitivity (Table 4-4), the FACT-Ga QoL measures corresponded well with 
clinical severity as indicated by Treatment Intent and Clinical Stage. Patients treated with curative 
intent rated their QoL higher than those treated for palliation. Patients diagnosed with an early stage 
of GC (AJCC stages 0, 1, 2, 3) scored higher than patients diagnosed with the late stage of the disease 
(AJCC stage 4). These observations were in line with the direction of the overall QoL measured by 
the EQ-5D utility, which was significantly different between the subgroups of both clinical variables.  
 
However, not all FACT-Ga scores showed statistical significance in the comparisons between clinical 
subgroups.  The EWB and FWB subscales, FACT-G and FACT-Ga were significantly different 
between curative and palliative patients with a moderate effect size from 0.56 to 0.74 (D.Ellis 2010), 
while for the Clinical Stage, only the GCS subscale achieved statistical significance with an effect 




Table 4-5. Multitrait-multimethod correlations matrix between EQ-5D domains and FACT-Ga subscales  
  
  
EQ-5D   FACT-Ga 
Pain Anxiety Usual Activities Mobility Self-care 
 
PWB EWB FWB GCS SWB 
EQ-5D 
           Pain/Discomfort 1 
          Anxiety/Depression 0.52
†
 1 
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The construct validity of FACT-Ga was further evaluated in the MTMM analysis using EQ-5D (Table 
4-5). Basically, the overall QoL quantified as the EQ-5D utility and as the FACT-Ga or FACT-G total 
score were strongly correlated (r = 0.70 and r = 0.66 respectively). The MTMM correlation matrix 
described in detail the inter-scale correlation patterns within either instrument, and more importantly 
across different instruments. The latter correlations connecting the EQ-5D domains with the FACT-
Ga subscales were summarized in the lower-left square of the MTMM matrix called the 
Heteromethod Block. As hypothesized a priori, the four monotrait-multimethod correlations 
highlighted in Table 4-5 are generally higher than the multitrait-multimethod correlations. The 
correlation coefficients of the PWB subscale with the Pain/Discomfort domain (r = -0.66) and the 
EWB subscale with the Anxiety/Depression domain (r = -0.57) are the highest in their respective 
columns and rows. The correlation coefficient of GCS with the Pain/Discomfort domain (r = -0.63) is 
comparable to that of the PWB subscale. The correlation between the functional QoL constructs, the 
FWB subscale in FACT-Ga and the Usual Activity domain in EQ-5D was -0.49. Despite being the 
strongest correlation in the Usual Activity domain column, it is weaker than the two multitrait-
multimethod correlations:  the Anxiety/Depression domain with the FWB subscale (r = -0.52) and the 
Mobility domain with the FWB subscale (r = -0.58). As the FACT-Ga SWB subscale and EQ-5D 
Self-care domain are not conceptually related to any QoL construct of the other instrument, the 
correlations involving these two QoL constructs are the lowest of the respective rows or columns.  
 
4.4 Discussion   
 
Our study validated FACT-Ga in a heterogeneous sample of Singaporean Chinese patients with GC. 
The study sample covered the full spectrum of clinical cases which would allow for applying the 
validated questionnaire to various diagnostic groups. To the best of our knowledge, this is the first 
study dedicated to validating FACT-Ga for the Chinese as the target population. Both English and 




For this sample of outpatients, the measurement ability of the FACT-Ga appears to be limited in 
evaluating the QoL outcomes of patients who survived GC relatively well. The ceiling effect was 
observed for all scores, especially the PWB, SWB and EWB subscales, for which the percentage of 
patients rating themselves in perfect health exceeded a notable value of 15% (Table 4-3). The core 
module FACT-G also showed a ceiling effect when applied to other types of cancer patients from the 
same study population (Cheung et al. 2009). A ceiling effect above 15% could have a negative impact 
on other psychometric properties of an instrument (Terwee et al. 2007), for example, the sensitivity to 
change, as supported by the finding that FACT-G is weak in detecting the improvement in a patients’ 
health status (Cheung et al. 2009; Garland et al. 2011)The evidence thus far seems to suggest that the 
existence of a ceiling effect of FACT-Ga compromises its potential as an evaluative QoL instrument.  
 
The FACT-Ga questionnaire showed sensitivity to the clinical characteristics of different patient 
groups, supporting FACT-Ga as a discriminative QoL instrument. Treatment Intent and Clinical Stage 
are important concerns for doctors to consider when making a clinical decision. The QoL profile 
described by the FACT-Ga scores corresponded very well to the clinical classification by the two 
variables (Table 4-4). The patients in a more severe situation, i.e., those treated for palliation or those 
with the disease in the advanced stage rated their life worse. For either overall or specific QoL 
aspects, it is clear that the group differences are in the direction theoretically hypothesized and 
consistent with the findings from the EQ-5D.    
 
Over and above its reflection of clinical severity of GC malignancy, the FACT-Ga scores exhibited 
differential sensitivity to clinical status. As suggested by the varying degree of the effect size and 
significance level of the t-test for each FACT-Ga score, the EWB and FWB subscales were sensitive 
to Treatment Intent, while the GCS and potentially the SWB subscales were sensitive to the patient’s 
clinical stage (Table 4-4). Furthermore, the FACT-Ga instrument revealed an interesting finding about 
the social aspect of the patient’s life, which was not measured in EQ-5D. The FACT-Ga SWB 
subscale scores were higher for severe cases than for less severe cases for both Treatment Intent and 
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Clinical Stage. This direction was opposite to that demonstrated by other scales. It would be too 
simplistic to ascribe the finding to random variation. We speculated instead that the Chinese culture 
played a part in this observation considering that our study population was Chinese. Sympathy is the 
essence of Chinese value systems and it could naturally be inferred that severe GC patients would 
receive more love and care from the people close to them. The SWB subscale is a measure of a 
patient’s self-perception of family support and emotional closeness to friends. Therefore, the reverse 
trend of SWB scores is not unexpected and possibly culturally-specific. 
 
In our study, the FACT-Ga instrument demonstrated excellent reliability in measuring the QoL of 
Chinese GC patients.  Except for the EWB subscale, Cronach’s α values indicated internal 
consistency reliability greater than 0.80 for the instrument and other subscales (Nunnally 1978). The 
EWB subscale had a Cronbach’s α of 0.62, comparable to 0.60 as previously reported (Garland et al. 
2011), yet below the generally accepted standard of 0.70 (Nunnally 1978). As the Cronbach’s α of a 
scale is computed based on the inter-correlations among its constituent items, the extremely low item-
to-scale correlation of the EWB subscale with its item GE2  (r = 0.08) was supposed to account for 
the suboptimal reliability of the EWB subscale (Ware and Gandek 1998). After excluding item GE2, 
the EWB subscale had an improved Cronbach’s α of 0.72.  
 
The Cronbach’s α of the SWB subscale was reported as 0.82, indicating excellent reliability of the 
SWB subscale, based on the 67 participants who completed the first six items of the SWB subscale. 
The seventh item of the SWB subscale, GS7 asking about the sex life of the patient, introduced a non-
response rate of 48% (n=32), which greatly reduced the sample size for computing the reliability 
index. The Cronbach’s α would drop to 0.77 based on the 35 participants with complete information 
for seven SWB items. Non-response to the item GS7 was common in FACT-G validation studies in 
different cancer populations (Cheung, Daniel and Ng 2006; Fairclough and Cella 1996). Excluding 
GS7 in the calculation of Cronbach’s α for the SWB subscale has been practiced to minimize the 
detriment of missing information (Cheung, Daniel and Ng 2006). Doing so also prevented an unstable 
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estimate of the reliability index due to an insufficient sample size, which was demonstrated by the 
Cronbach’s α varying from 0.26 to 0.86 in five small samples (n=15) validating the FACT-Ga (Debb 
et al. 2011).    
 
Construct validity of FACT-Ga was explored internally by examining the item-to-scale correlations 
for each item and externally by contrasting with EQ-5D. As hypothesized a priori, most items 
converged around their individual master subscales as required for good convergent validity. 
However, the Pearson correlation coefficient of item GE2 with the EWB subscale was only 0.08 with 
a 95% CI below 0.4. It was also associated with a definite scaling error implying that item GE2 
should be included in the FWB subscale rather than the EWB subscale when FACT-Ga is used in 
Chinese GC patients (Ware and Gandek 1998). This finding supports the results of previous cross-
cultural studies investigating the factor structure of the FACT-G in Asian populations (Fumimoto et 
al. 2001; Yu et al. 2000) 
 
External validation involves a MTMM correlation matrix correlating the FACT-Ga subscales with the 
EQ-5D domains. The similar QoL constructs which were specified separately for EQ-5D and FACT-
Ga yielded stronger monotrait-multimethod correlations than the multitrait-multimethod correlations 
in the Heteromethod block (Table 4-5). As shown by the monotrait-multimethod correlation 
coefficients, the PWB, EWB and GCS subscales are measuring the QoL aspects as intended. They are 
also able to discriminate the different aspects of a patient’s life (Trochim 2006). With regard to a 
patient’s functionality, the FACT-Ga FWB subscale was not strongly related to the Usual Activity 
domain of EQ-5D as we hypothesized, but to two EQ-5D domains, the Mobility and 
Anxiety/Depression domains, with similar strengths of correlation (r = -0.58 and r = 0.52 
respectively). This may reflect the fact that the SWB subscale score is an integration of the mental and 
physical functions of a patient’s life. The QoL constructs which are covered by only one questionnaire 
had the lowest cross-instrument correlations, for example, the SWB subscale of FACT-Ga and the 
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Self-care domain of EQ-5D. These results confirmed and substantiated the convergent and 
discriminant validities of FACT-Ga.    
 
However, several limitations in this study must be noted. We were only able to recruit outpatients 
who usually have a better current QoL and prognosis than those hospitalized for radical treatments or 
bedridden at home. We acknowledge that the validity and reliability estimates were influenced by the 
narrow sampling due to logistical difficulties (Victorson et al. 2008). However, considering the 
statistical property of Cronbach’s α and the correlations indicating construct validity, a more 
heterogeneous study sample generated by a wider patient pool would strengthen the current estimates 
(Peter M. Fayers 2007). With a cross-sectional sample, we were also unable to assess test-retest 
reliability and the responsiveness of FACT-Ga measures to QoL change over time.   
 
4.5 Conclusion  
 
Our study demonstrated that, when used in a Chinese population, FACT-Ga is able to detect group-
differences in QoL outcomes between clinically distinct patient groups. The total and subscale scores 
from FACT-Ga can be considered reliable and valid measures of the QoL of Chinese patients with 
GC. This evidence supports the use of FACT-Ga as a discriminative QoL instrument alone or as a 




5 CHAPTER V:  COST EFFECTIVENESS ANALYSIS -    MARKOV MODEL 
CONSTRUCTION  
 
5.1 Gastric Cancer Prevention – From Mass Screening to Focused Surveillance 
 
 Mass screening for GC has shown to significantly improve patient survival (Hosokawa et al. 2008; 
Lee et al. 2006; Miyamoto et al. 2007). However, it is still hard to justify the establishment of 
population-based screening in a country with low or intermediate GC risk because of concerns about 
cost-effectiveness. Hence, cost-effectiveness evaluations of population-based screening are currently 
limited to jurisdictions with the highest GC incidences in the world, such as Japan, South Korea and 
Taiwan (Chang et al. 2012; Lee et al. 2007; Tsuji,Tsubono and Hisamichi 2001). Due to the dramatic 
impact of level of GC risk in a population on cost-effectiveness, the findings from these economic 
evaluations may not be generalizable to other populations.  
  
Endoscopic surveillance, whereby patients with precancerous lesions are closely followed up for GC 
development by scheduled OGD examinations, has previously demonstrated  the ability to detect GC 
at an earlier curable stage (Whiting et al. 2002). Multiple studies have provided evidence about the 
clinical benefit and cost-effectiveness of endoscopic surveillance in patient subgroups with atrophic 
gastritis, intestinal metaplasia, gastric ulcer or dysplasia (Dinis-Ribeiro et al. 2007; Hassan et al. 2010; 
Yeh,Ho and Hur 2010; Yeh et al. 2010). Thus, OGD-based surveillance is worthy of further 
investigation into its economic potential as a national strategy for GC prevention in countries at low to 
intermediate GC risk where mass screening is hardly warranted. The recommended OGD frequency 
for surveillance is once every year (Table 5-1).  
 
In Singapore, the dominant Chinese population overall is at an intermediate risk for GC. The interest 
in early detection to improve the survival and quality of life of GC patients has stimulated a series of 
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endeavors. Based on decision-analytic models, Dan et al. reported that 2-yearly OGD screening is 
cost-effective in Singaporean Chinese men aged 50-70 years (Dan, So and Yeoh 2006); while Xie et 
al. evaluated the primary prevention strategy of Helicobacter Pylori screening and eradication in 
Singaporean Chinese aged 40 years or older (Xie et al. 2008). Additionally, an ongoing hospital-based 
demonstration project, GCEP (Zhu et al. 2009), was initiated in 2004 with the intention to provide 
empirical evidence on the feasibility and cost-effectiveness of endoscopic surveillance.  
Table 5-1. Endoscopy frequency recommended for endoscopic surveillance for gastric cancer  
Precancerous lesions  Surveillance Reference 
Mild atrophic gastritis Annual OGD (Graham and Asaka 2010) 
Moderate or severe atrophic gastritis Annual OGD (El-Zimaity et al. 2001) 
Intestinal metaplasia type II & III Annual OGD (Kapadia 2003) 
Low grade dysplasia Annual OGD (Bustamante et al. 2002) 
Gastric ulcer suspicious of cancer Annual OGD (Whiting et al. 2002) 
 
However, consensus has yet to be reached regarding the optimal strategy for GC secondary prevention. 
Furthermore, none of these aforementioned studies have provided evidence regarding cost-
effectiveness. Hence, to fill in this crucial knowledge gap to assist decision makers and clinicians, we 
constructed a Markov Model to compare the cost-effectiveness of OGD-based focused surveillance 
and mass screening. Our main objectives were to: (1) inform the choice of optimal strategy for 
secondary prevention of GC within the context of the Singapore healthcare system; and (2) provide 
suggestions for actual implementation of a GC screening or surveillance program in a country at 
intermediate GC risk. Besides providing information about cost-effectiveness of various programs for 
the decision makers in Singapore, our model could be adapted for use in other locales. While the cost 
and outcome values are expected to be different in different jurisdictions, our model can provide a 





5.2 Research Frame of Cost-Effectiveness Analysis Endoscopic Surveillance    
 
5.2.1 Target population  
The target population was defined as Chinese aged 50-69 year old.  According to Singapore Cancer 
Registry (Singapore Cancer Registry Committee 2012), there is a sharp increase in GC risk after the 
age of 50 years and the defined population carries most of GC burden (90%). 
 
 Although people aged 70 years or older have even higher risk of GC, they are not recommended for 
preventive programs for two reasons: (1) the possibility of extending their life expectancy is slim 
given their old age, and the extra OGD examinations and ensuing clinical management are proven 
unnecessary and ineffective (Dan, So and Yeoh 2006); and (2) compliance in this age cohort is always 
low, as a consequence, cost effectiveness is not satisfactory (Cho et al. 2013). Furthermore, as data 
suggests (Ministry of Health 2004), a 70-year person tends to suffer from multiple comorbidities with 
most prevalent diseases being diabetes and heart disease. These competing diseases make GC 
screening less of a health priority, especially when the subject does not present with gastric symptoms 
(Kye, Han and Park 2010).  
 
5.2.2 Endoscopy/Biopsy protocol  
OGD/biopsy protocol is standardized in consideration of test characteristics of sensitivity and 
specificity, and social factors of accessibility and availability of endoscopy in Singapore healthcare 
system. The OGD/biopsy protocol consists of two parts: 1) ordinary OGD examination to identify 
stomach lesions based on morphologic alteration of stomach mucosa, and 2) detailed biopsy to 
provide histological results.  
 
Six sites defined as below were selected for sampling (Figure 5-1).   
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1) A1- lesser curvature of the antrum, within 2-3cm of the pylorus;  
2) A2- greater curvature of the antrum, within 2-3cm of the pylorus;  
3) IA- incisura angularis;  
4) B1- lesser curvature of the corpus, 4cm proximal to the angulus;  
5) B2- middle portion of the greater curvature of the corpus, 8cm from the cardia;  
6) Cardia (C) - within 1 cm below the OGJ (defined as the point where gastric folds disappear).  
 
Stomach mucosa will be biopsied each from A1, A2, IA, B1, B2 and C, and fixed for histology. The 
fresh biopsy from A1 will be used for Helicobacter pylori genotyping. This standardized procedure is 
used in both screening and surveillance in this project. 
 
Figure 5-1. Biopsy sites during endoscopy examination in screening and surveillance   
 
5.2.3 Strategies in consideration  
A decision analytic model was previously used to explore the cost-effectiveness of secondary 
prevention of GC in the same target population. The authors recommended that 2-yearly OGD 
screening is cost-effective for GC prevention in Chinese males age 50-70 year old (Dan, So and Yeoh 
2006). Since 2-yearly OGD screening is already an option in Singapore, we felt compelled to make a 
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head-to-head comparison between surveillance and screening, following good practice of modeling 
study (Weinstein et al. 2003).  
 
5.2.3.1 Endoscopic screening  
 
To implement the 2-year OGD screening, the target population would be divided into two halves. In 
any given year, only one half of the population undergoes follow-up OGD. In this way, the two halves 
undergo OGD in tandem so that the entire target population undergoes an OGD examination once 
every two years. Our model assumed that the OGD follow-up will continue until a subject dies or is 
diagnosed with GC.  
 
5.2.3.2 Endoscopic surveillance 
 
For OGD surveillance, the defined target population would be screened at baseline with a 
standardized OGD procedure (Figure 5-2). H. pylori infection, if detected, would be eradicated using 
the standard triple-therapy regimen (Talley, Fock and Moayyedi 2008). We based the 
recommendation of OGD follow-up on histological examination of stomach mucosa. Those 
presenting with precancerous lesions (Bustamante et al. 2002; El-Zimaity et al. 2001; Graham and 
Asaka 2010; Kapadia 2003; Whiting et al. 2002) will be categorized as high risk subjects and would 
be subjected to annual OGD follow-up. Those without precancerous lesions would be categorized as 
low risk, and would not require further ODG follow-up. The number of subjects undertaking OGD 
surveillance is determined by the prevalence of premalignant gastric lesions. As in the screening 




Figure 5-2. Overview of the surveillance strategy 
 
5.2.4 Determination of societal willingness-to-pay 
Following the guidelines of World Health Organization (Commission on Macroeconomics and Health 
2001), the Singapore GDP of $46,200 per capita for year 2011 was used as the willingness-to-pay 
(WTP) threshold. The GDP is country-specific so this WTP of $46,200 /QALY serves as a benchmark 
unique to Singapore in judging the cost-effectiveness of the evaluated strategy. A strategy associated 
with an ICER less than $46,200/QALY is considered cost-effective in our project.  
 
5.3 Markov Model Development  
 
The decision-analytic model most commonly used for disease simulation is the Markov model 
(Barbosa et al. 2010). Markov model is a state transition model which is able to simulate the dynamics 
of disease and associated clinical intervention over a long period of time in a specified population. We 
adopted a healthcare system perspective instead of a societal perspective, as one of the major purposes 
of this project is to inform the implementation of a surveillance program within the Singapore 




In this chapter, we illustrated the process of model construction step by step using TreeAge software 
version Pro 2009 (TreeAge Software, Inc., Williamstown M.A., USA).  We provided detailed 
explanations about the theories and thoughts regarding model structure, equations, parameter values, 
assumptions and some TreeAge techniques. By presenting the model this way, we aimed to give 
readers a clear picture about Markov model construction and allow them to evaluate our model at high 
level of mathematical and clinical detail. As the model is designed to have multi-applications, we 
hope that, with appropriate modification of our model, readers can develop their own models to 
address their specific research problems.  
 
5.3.1 Thought experiment before model development 
To the best of our knowledge of the natural history of GC and related clinical practice, we have 
presented an overview of the clinical pathways of the target population at GC risk using a simple 
schematic diagram (Figure 5-3).  
 
Figure 5-3. Overview of clinical pathway of target population developing gastric cancer  
Arrowed lines represent transitions from one state to a different state. If a subject remains in original health 
state, an arrowed curve was used.  
 
Three mutually exclusive health states were defined (Figure 5-3). A subject in an asymptomatic state 
means that the person is free of GC, and therefore considered healthy in general; a Gastric cancer state 
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means a subject has been diagnosed and is currently living with GC; and a Death state indicates the 
death event to either a healthy person or GC patient. In any given year (a Markov cycle in our model), 
a subject of the target population stays in only one of three health states. Transitions among health 
states were driven by the clinical events of death and diagnosis of GC. As shown in Figure 5-3, once a 
subject is diagnosed with GC, biologically he is not able to regress to a state of being GC-free, 
reflecting that biologically there is no cure for a cancerous disease. A person who is already dead 
cannot return to a state of being alive, asymptomatic or Gastric Cancer. The Death state is called the 
absorbing state in the Markov model.    
 
As stated in Chapter II, the cancer staging is important in guiding clinical management and public 
health programs. To evaluate the down-stage effect of preventive strategies, it is necessary to present 
the clinical stages of GC in our model, which would be represented by additional Markov states.  
Therefore, the GC state in Figure 5-3 was divided into four states corresponding to the clinical staging 
system of GC (Clinical Stage 1, Clinical Stage 2, Clinical Stage 3 and Clinical Stage 4) (Figure 5-4).  
 
In Figure 5-4, we highlighted the problem associated with the current practice of no OGD prevention. 
At present, Singapore has not yet installed public health programs for GC prevention. The majority of 
GC patients are diagnosed with advanced cancer (Stage 3 & Stage 4) (Koong et al. 1996) when 




Figure 5-4.  Overview of clinical pathway of present situation without gastric cancer prevention 
1) Arrowed lines represent transitions from one state to another. If a subject remains in the original health state, 
an arrowed curve was applied.2) The area of the cycle represents the proportion of each clinical Stage in  
diagnosed GC cases 
 
 
However, as shown in Figure 2-1, GC development is a years or even decades-long process (Liu et al. 
2006). Accordingly, there is a long preclinical phase during which clinical interventions like screening 
or surveillance are capable of detecting gastric premalignancies and potentially making earlier 
diagnoses of GC. With scheduled OGD follow-up of patients with atrophic gastritis, intestinal 
metaplasia and dysplasia, it could be expected that a greater proportion of GC cases are diagnosed 
with early stage diseases (Nakashima et al. 2010), in contrast to the usual care where the majority of 
GC patients have advanced disease (Wai et al. 2002). This shift of stage distribution of GC patients is 





Figure 5-5. Expected effect of stage-shift by gastric cancer prevention programs  
1) Arrowed lines represent transitions from one state to a different state. If a subject remains in original health 
state, an arrowed curve was applied.2) The area of the cycle represents the proportion of each clinical Stage 1n 
all diagnosed GC cases 
 
 
5.3.2 Building Markov model with TreeAge software 
We used the commercial software TreeAge to build the Markov model. TreeAge was chosen because 
the software is user-friendly, visually based and less prone to mistakes than program-based software 
like Microsoft Excel (Menn and Holle 2009).  TreeAge presents the Markov model in a graphical 
form known as a cycle tree. Figure 5-6  shows the basic TreeAge structure comparing the Markov 
models for screening, surveillance and no OGD intervention.   
 




The completed Markov trees are presented in the figures that follow.    
 













5.4 Expansion and Population of the Markov Tree  
  
Developing a simple diagram (Figure 5-4 and Figure 5-5) into a complex TreeAge Markov tree 
(Figure 5-7, Figure 5-8 and Figure 5-9) populated with a large amount of data constitutes the primary 
part of the modeling process. This process normally consisted of three parts: (1) defining Markov 
states which represent the major clinical events in the course of disease prognosis; (2) designing a 
Markov model structure to simulate clinical pathways composed of Markov states. The complexity of 
the structure is jointly determined by the availability of data and the extent to which the modeler 
wishes to reflect clinical reality; (3) populating the Markov model with the best-available data about 
diagnosis, treatment, disease history, epidemiology, cost and utility. The target population was 
modeled year by year until 99% of the cohort died, which is the termination condition for a TreeAge 
programmed Markov model.    
 
Defining Markov states: Based on the thought experiments, we defined seven Markov states for no 
OGD intervention strategy, namely, asymptomatic (branch “usual care”, Figure 5-7), GC stage 1, GC 
stage 2, GC stage 3 and GC stage 4, death from GC and death for other reasons. The asymptomatic 
state was divided into two categories for the screening strategy representing alternate OGD 
examination of the target population (branch “without OGD screening program” and branch “outside 
OGD screening program” Figure 5-8). For the surveillance strategy, the asymptomatic state was 
divided into three categories corresponding to three populations with different GC risk (branches 
“ high risk for surveillance”, “low risk without surveillance” and “baseline OGD”, Figure 5-9). The 
Markov states representing death event and GC stages are the same for all the three strategies.  
 
Designing Model structure: Based on the diagrams of Figure 5-4 and Figure 5-5, TreeAge model 
structure was designed to depict the clinical pathway which the target population will go through each 
of the three strategies. In any given model, the simulation starts with the asymptomatic state, i.e. the 
target population is at risk of GC but clinically is free of the malignancy. As the model progresses, 
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some individuals of the cohort develop GC. These GC patients are diagnosed with different clinical 
stages and represented by the Markov states for clinical stages in the models. GC patients 
subsequently receive standardized stage-specific treatment therefore achieve stage-specific survival. 
GC patients and healthy subjects all are exposed to background mortality. Finally, the total cohort 
reaches its life expectancy and the model terminates the simulation. For the screening and surveillance 
process, the models incorporated the practice of OGD follow-up.   
  
Data synthesis:  As we retrieved data from various study designs, it would be inappropriate to use 
them in the model without carefully evaluating their quality in terms of internal validity, reliability 
and generalizability to our situation. Published data were the primary sources for parameters inputted 
in our model. In the event that required data were not available in publications, expert opinions (Dr. 
Dan Yong Yock, a consultant gastroenterologist in NUH) were sought as the best estimates 
(Weinstein et al. 2003). Data which were obviously “outliers” would not be used. Any reasonable data 
range would be identified for the subsequent sensitivity analysis. TreeAge techniques were tried and 
tested to ensure that the data were accurately represented when the model runs. 
 
The modeling started with no OGD intervention because it is technically simple. Upon completion of 
that Markov tree, the model structure was modified to incorporate the additional data associated with 
the screening and surveillance strategies to be evaluated. The skeletons of the Markov subtrees were 
consistent thus improving the comparability between the three strategies. The following sections 
illustrate how we handled the important issues in constructing Markov models. We presented the 
contents by showing how the information was treated differently among the three strategies.  
 




5.4.1.1 Gastric Cancer Development with no OGD Intervention  
 
 
Figure 5-10. Gastric cancer development in the general population with no OGD intervention 
 
As in Figure 5-10, GC occurrence in the target population was denoted by the branch GC clinically 
diagnosed (highlighted) indicating that GC patients in Singapore are diagnosed in a general clinical 
setting. The probability of developing GC in a healthy population was estimated by incidence data 
from the Singapore Cancer Registry  a population-based survey conducted every 5-years in Singapore 
(Singapore Cancer Registry Committee 2012).  
 
We did not use point estimation of GC incidence for the target population (27.6/100,000), as it 
provides no information about the incidence variation by age and gender (Table 5-2). For the purposes 
of data precision, information from Table 5-2 was applied in the model.  
 
The original data of the Registry was organized in 5-year age cohorts, which assumes that each 5-year 
cohort is homogeneous in terms of GC risk. For example, the incidence of GC in the 50-54 age cohort 
is 12/100,000, implying that the GC risk is the same for a person of 50 years as that for a person of 54 
years old. However, given the positive association between age and GC risk (Guggenheim and Shah 
2013), a 54-year person has a higher GC incidence than a person aged 50 years. Using the overall 
incidence of 5-year cohorts GC risk for younger age groups within that cohort were overestimated, 
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but underestimated for older age groups. Justifying its use in the model, we were forced to assume 
that the overestimation will be offset by the underestimation, which may not always hold true as the 
population size shrinks for older age cohorts. To fit the yearly Markov cycle, the information in Table 
5-2 was reorganized as yearly data as in Table 5-3 
 
Population incidence as reported by the Registry was the best available data to represent GC risk in 
Singapore. This practical limitation due to data availability is unavoidable for any modeling study. 
However, the Registry data can reflect the age trend of GC risk to a reasonable extent. These trends 
are more precise than a point estimate for the entire target population.  
Table 5-2. Gastric cancer incidence reported by the Singapore Cancer Registry (1/100,000) 
Age Overall Male Female  
50 - 54 12 13 11 
55 - 59 19 26 13 
60 - 64 36 50 22 
65 - 69 69 93 48 
70 - 74 105 157 61 
75 - 79 193 284 123 
80 & over 194 295 133 
The age groups in bold are our target population.  
 
TreeAge technical specification: 
 
Table 5-3 is age and gender-indexed. When the target population survives one Markov cycle, 
TreeAge will choose the incidence corresponding to the cohort’s age and gender until the model 
terminates. If a subject is modeled above the age of 80 years, the risk of GC remains at the incidence 





Table 5-3. Gastric cancer incidence by age and gender in the Markov model (1/100,000) 
Age  Overall Male Female Age  Overall Male Female 
50 12 13 11 70 105 157 61 
51 12 13 11 71 105 157 61 
52 12 13 11 72 105 157 61 
53 12 13 11 73 105 157 61 
54 12 13 11 74 105 157 61 
55 19 26 13 75 193 284 123 
56 19 26 13 76 193 284 123 
57 19 26 13 77 193 284 123 
58 19 26 13 78 193 284 123 
59 19 26 13 79 193 284 123 
60 36 50 22 80 194 295 133 
61 36 50 22 
    62 36 50 22 
    63 36 50 22 
    64 36 50 22 
    65 69 93 48 
    66 69 93 48 
    67 69 93 48 
    68 69 93 48 
    69 69 93 48         
(Singapore Cancer Registry Committee 2010) 
 
5.4.1.2 Gastric Cancer Development under the Screening Strategy  
 
Screening, as a secondary prevention strategy aiming for early detection, is not supposed to change 
the GC risk, i.e. GC incidence (Lee et al. 2006; Tsubono et al. 2000). The screening strategy evaluated 
in our study involves a 2-year cycle consisting of one year with OGD examination and the other year 
without. Therefore, although the GC incidences are the same for screening-years and non-screening-
years, the data have to be treated differently (Figure 5-8).   
 
As shown in Figure 5-11, during non-screening-years (branch “outside OGD screening program”), 
the GC development in the target population was represented by the incidence data of the Registry as 





Figure 5-11. Gastric cancer detected during years without follow-up OGD 
 
However, during the screening-years of the screening strategy (Figure 5-12, branch within OGD 
screening program), the model should account for characteristics of the screening test, which refer to 
the sensitivity and specificity of OGD examination in particular.  
 
 
Figure 5-12. Gastric Cancer detected by screening OGD  
 
To correctly simulate the influence on GC incidence by the screening strategy using OGD with given 
sensitivity and specificity as a screening tool, we had to examine the mechanisms of secondary 
prevention. In theory, OGD screening is unable to change the GC incidence. In reality, a screening 
program would definitely detect at least the same number of GC cases as no OGD intervention, if not 
more cases as a result of false positive and over-diagnosis (Tomizawa et al. 2013).  Therefore, in 
building the structure of Figure 5-12, we assumed that all false positive cases (branch “False GC”) 
were identified and excluded by confirming tests and that there were no over-diagnosed cases. This 
practice is considered acceptable (Knudsen,McMahon and Gazelle 2007).  
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The branch True GC denotes the GC patients detected by the screening program. Its associated 
probability is Positive Predictive Value (PPV) conditional on a positive screening OGD whose 
likelihood is denoted by Minimum Positive Rate Of Screening given the GC risk in the target 
population. Mathematically, the product of the Minimum Positive Rate Of Screening and Positive 
Predictive Value (PPV)  results in the GC incidence projected by the structure of Figure 5-12. In 
TreeAge, a function called Bayesian Revision was enabled to carry out these computations using the 
input parameters of the sensitivity and specificity of OGD and population GC incidence. 
Consequently, the screening strategy projected a GC incidence similar to those reported by the 
Singapore Cancer Registry.  
 
5.4.1.3 Gastric Cancer Development under the Surveillance Strategy  
 
For the surveillance strategy (Figure 5-2), risk of developing GC was assessed in three subgroups, i.e., 
in the general population at baseline (Figure 5-13, branch Prevalent GC Cases), in high risk cohort 
(Figure 5-15, branch OGD positive) and in low risk cohort (Figure 5-14, branch GC clinically 
diagnosed). Since GC risk is different in these three groups (general population, high risk and low risk 
cohorts), the GC incidence data were adjusted to reflect this variation of GC risk as follows.  
 
5.4.1.3.1 Gastric cancer development in the general population at baseline 
 
As shown in Figure 5-2, a baseline OGD was administered to the target population to identify the high 
risk subjects with precancerous lesions. Actually, GC patients would be also detected at the same time 
(Figure 5-13, branch Prevalent GC cases). The GC patients diagnosed this way are referred to as 
prevalent cases indicating that they are existing cases not yet diagnosed and thus there is no benefit of 
early detection by screening. These cases (Figure 5-13, variable tPrevalentGC) were represented by 




One may argue that GC prevalence, rather than GC incidence, should be used at this point. However, 
prevalence by definition not only includes these prevalent cases, but also GC patients who were 
previously diagnosed and therefore ineligible for the screening. Using GC prevalence in our model 
would overestimate the GC case-load for the strategy.  
 
 
Figure 5-13. Gastric cancer development at baseline of the general population  
 
5.4.1.3.2 Gastric cancer development for high and low risk cohorts  
 
The key characteristic of surveillance in contrast with screening is to differentiate the target 
population by risk of developing GC. In the case of our surveillance strategy, the target population 
would be dichotomized into high and low risk cohorts at a baseline OGD examination of stomach 
mucosa. The high risk cohort comprises persons with precancerous gastric lesions. However, the 
precancerous lesions evaluated in our model were broadly defined. This point is different from 
previous studies (Dinis-Ribeiro et al. 2007; Hassan et al. 2010; Yeh,Ho and Hur 2010; Yeh et al. 2010) 
which defined the specific precancerous lesion in their modeling. In those studies, incidence rates 
indicating GC progression have to be estimated individually from external resources.   
 
Using a broad definition for precancerous lesions, our model emphasized the excessive GC risk 
measured as odds ratios (OR) for GC attributable to certain gastric lesions. Then by simulating the 
effect of distinctive ORs on the model outcomes, our model is able to examine a wide spectrum of 
gastric lesions. To estimate GC incidences for high and low risk cohorts, we adopted an 
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epidemiologic concept called Attributable Risk, with the GC incidence of low risk subjects given by 
the following equation.  
 Incidence/ {[(OR-1)*Prevalence-of-Precancerous-Lesion]+1} 
Equation 1. Progression rate of gastric cancer in the low risk cohort 
 
The GC incidence of high risk subjects is given by the following equation. 
Incidence*OR/ {[(OR-1)*Prevalence-of-Precancerous-Lesion]+1} 
Equation 2. Progression rate of gastric cancer of the high risk cohort 
 
Actually, these two equations are adjusted forms of attributable risk to calculate the incidences of 
cohorts with specific ORs in a single population. 
 
Similarly as for the Markov models of screening and no OGD intervention, Equation 1 and Equation 2 
use age and gender specific incidences in Table 5-3. Gastric cancer incidence by age and gender in the 
Markov model (1/100,000) in the TreeAge model is shown in Figure 5-14 and Figure 5-15.  
 
The second parameter in the equation is the OR, which quantifies the GC risk attributable to 
precancerous lesions in the target population. With OR incorporated into the two equations, the GC 
risk estimated for the two risk cohorts which are clinically categorized by surveillance OGD, will be 
linked epidemiologically. As a consequence, the overall GC risk of the target population remains 
constant when our model simulates surveillance scenarios involving different precancerous gastric 
lesions. If the progression rates were estimated separately from different studies, this would risk the 
mistake that the overall GC risk would change in different scenarios.  
 
 The third and last parameter in the equations is the prevalence of the precancerous lesion. This 
parameter has to come from a Singapore-based population study because our study is stringently 
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Singapore specific. Even though there may be no well-designed survey to give a reliable estimate, the 
Markov model can examine the influence exerted by the variation of the prevalence of precancerous 
lesions using deterministic and/or probabilistic sensitivity analysis. This approach may be useful for 
decision-making.  
 
Using the incidences from the Singapore Cancer Registry, ORs and prevalence of precancerous 
lesions in the two equations has helped to improve the comparability among Markov models in our 
project and avoid the problem of data transferability. As a result, the model is more Singapore-
specific, clinically relevant and less dependent on the quality of external data. This is considered good 
practice by experts  (Drummond 2005).   
 
 
Figure 5-14. Gastric cancer development in the low risk cohort 
 
In the Markov structure for the low risk cohort, Equation 1 was used to represent the progression rate 
from asymptomatic to GC (Figure 5-14, variable prob_ProgressionRateOfLowRiskSubjects).  For the 
high risk cohort, Equation 2 was represented by the product of MinimumPositiveRateOfSurveillance 





Figure 5-15. Gastric cancer development in the high risk cohort 
   
5.4.2 Gastric cancer survival   
 
When building the Markov models, we assumed that the survival experience after a diagnosis of GC 
would be the same irrespective of how the disease is diagnosed. For example, the annual probability 
of survival for a Stage 1 GC case is the same whether it is detected by a screening or surveillance 
OGD or diagnosed clinically under usual care of no OGD intervention.   
 
After the diagnosis of GC, two distinctive clinical phases were defined as they had different clinical 
management strategies and accordingly different probabilities of survival. Phase 1 referred to the 
initial six months being diagnosed with cancer, during which a GC patient would receive aggressive 
diagnostic and therapeutic procedures. The probability of death in this phase was relatively higher 
(Environmental Protection Agency USA 2000; Munene et al. 2012). If the patient survived the acute 
treatment, he entered the Phase 2 when medical care was relatively less aggressive and the probability 
of death was stable.  
 




The preliminary model has simulated two phases of GC survival. To model Phase 1, the TreeAge 
structure was initially designed as in Figure 5-16 (highlighted by bold boxes). Considering a real life 
scenario, GC patients can suffer an acute death from surgery, infection and complications of disease 
progression and chemotherapy, among others during Phase 1. The below structure requires the in-
hospital mortality of GC patients.  
 
Figure 5-16. Gastric cancer diagnosis and treatment with simulation of in-hospital mortality  
 
 
However, in-hospital mortality data is not available for Chinese patients with GC in Singapore. We 
have considered using the data reported for western populations (Wu et al. 2000). After consultation 
with one of the collaborators, Dr. Dan Yock Young, a senior consultant in gastroenterology, we 
decided that the non-Singaporean data were not transferrable to our setting, as this would compromise 
model validity. Thus we chose not to specifically model Phase 1 of patient survival. The TreeAge 
structure of Figure 5-16 was reduced to that shown in Figure 5-17. 
 




If in-hospital mortality data were available, they would be inputted into the Markov models for the 
three strategies. We believe that adding the same data into the models would only minimally affect the 
comparisons among the three strategies. In other words, even without detailed modeling on this phase, 
bias is unlikely. The limitation of our current models is that the survival rate in the first year could be 
slightly overestimated because of the exclusion of the in-hospital mortality data.   
 
5.4.2.2 Gastric cancer survival in Phase 2 (after the first six months) 
 
The second phase represents the clinical stage when the disease is generally stable under routine GC 
care, and thus the probability of survival is relatively low (Figure 5-18, branches “Survival with GC”). 
The annual probability of survival was derived from 5-year survival rates for each stage reported on 
the target population (Koong et al. 1996). The present model did not take into account of the effect on 
survival of age, gender or other variables. This practice is based on the assumption that the survival 
rate is generally homogenous in the patient cohort defined by the GC stage (Table 5-4).  
 
Table 5-4. Annual probability of gastric cancer survival by clinical stage (%) 
GC Stage GC Survival 
Stage 1 96.56 
Stage 2 91.79 
Stage 3 82.01 
Stage 4 9.25 
(Koong et al. 1996; Singapore Cancer Registry 2011) 
 
As in Figure 5-18, the four GC clinical stages are modeled separately and populated with stage-
specific survival data. The simulation of the concurrent death event (due to GC or other reasons) is 





Figure 5-18. Stage specific gastric cancer survival 
 
Stage-specific survival is the foundation for secondary prevention of GC. By separately modeling 
prognosis of GC patients of different stages, our model truthfully reflected the survival advantage of 
early stage GC cases that accounted for a bigger proportion of the patient cohort having been exposed 
to the screening or surveillance strategy. The favorable stage-shift due to the secondary preventive 
measures was translated into clinical outcome in our model.  
 
5.4.3 Death   
 




The mortality event in our model is classified into two categories by reason for death (branches 
“Death from GC” and “Death for Other Reasons”). This is to illustrate the effect of mortality 
reduction by early detection. Early GC patients have a better prognosis than those with advanced 
stage. Surveillance and screening strategies are designed to detect more early stage GC cases in 
comparison with the no OGD intervention and therefore achieve better survival of the target 
population. So we hypothesized that the GC-specific mortality represented by the Branch “Death 
from GC” would be smaller in the model outputs for the screening and surveillance strategy than that 
for the no OGD intervention. 
 
“Death from GC” is straightforward in the model. “Death for other reasons” has to be considered in 
two different scenarios. The first scenario is presented in Figure 5-20 where “Death for other reasons” 
means the co-mortality due to other reasons for a healthy member. The second scenario is presented in 
Figure 5-21 where “Death for other reasons” means the competing mortality for a patient already 
diagnosed with GC. Mathematically, this mortality received different representation in the two 
scenarios.  
5.4.3.1 Probability of death for other reasons for a healthy subject 
 
 




The probability of death for other reasons for a healthy subject, or the co-mortality of the target 
population (Figure 5-20, branch Death for other reasons), was estimated by the age and gender-
specific probability of dying reported in the Life Table of Singapore population 2011 (Department of 
Statistics Singapore 2012). The information from Table 5-5 was incorporated in the model to 
represent the co-mortality of the target population.  
Table 5-5. Probability of dying at each age of the Singapore Chinese population  
Age  Overall Male Female Age  Overall Male Female 
50 0.24% 0.31% 0.17% 76 3.18% 4.07% 2.47% 
51 0.26% 0.34% 0.18% 77 3.52% 4.49% 2.78% 
52 0.29% 0.37% 0.20% 78 3.91% 4.94% 3.13% 
53 0.32% 0.41% 0.22% 79 4.31% 5.42% 3.51% 
54 0.34% 0.45% 0.24% 80 4.72% 5.90% 3.90% 
55 0.37% 0.49% 0.26% 81 5.14% 6.40% 4.30% 
56 0.40% 0.53% 0.28% 82 5.62% 6.96% 4.74% 
57 0.44% 0.57% 0.31% 83 6.19% 7.66% 5.27% 
58 0.48% 0.63% 0.34% 84 6.86% 8.48% 5.89% 
59 0.53% 0.69% 0.38% 85 7.56% 9.33% 6.55% 
60 0.58% 0.74% 0.42% 86 8.33% 10.25% 7.27% 
61 0.63% 0.81% 0.46% 87 9.16% 11.26% 8.06% 
62 0.70% 0.90% 0.51% 88 10.07% 12.35% 8.93% 
63 0.80% 1.02% 0.58% 89 11.07% 13.53% 9.87% 
64 0.90% 1.17% 0.65% 90 12.15% 14.81% 10.91% 
65 1.02% 1.32% 0.73% 91 13.32% 16.19% 12.03% 
66 1.13% 1.48% 0.81% 92 14.59% 17.68% 13.26% 
67 1.25% 1.64% 0.90% 93 15.96% 19.28% 14.59% 
68 1.38% 1.81% 0.99% 94 17.45% 21.00% 16.03% 
69 1.51% 1.98% 1.10% 95 19.05% 22.85% 17.59% 
70 1.65% 2.15% 1.20% 96 20.77% 24.82% 19.26% 
71 1.79% 2.34% 1.31% 97 22.62% 26.93% 21.07% 
72 1.98% 2.58% 1.47% 98 24.60% 29.17% 23.00% 
73 2.24% 2.91% 1.68% 99 26.72% 31.55% 25.07% 
74 2.54% 3.28% 1.94% 100 100% 100% 100% 
75 2.86% 3.67% 2.20% 101 
   
(Department of Statistics Singapore 2012) 
 
The Life Table would slightly over-estimate this probability since GC contributed to the overall 
background mortality of the Singapore population (Singapore Cancer Registry Committee 2012). 
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However, this over-estimation is normally considered insignificant in comparative modeling studies 
(Weinstein et al. 2003).   
As Life Table calculation aggregates the deaths after a person reaches 100 years, the death rate for an 
age cohort of 100 years increases to 100% from 26.7% for a 99-year age cohort (Table 5-5, 
highlighted in bold fonts). We extrapolated the oldest age to 101 years by assuming that a Chinese 
person is definitely dead in two years after age of 99 years. Then recalculating the probability of death 
for age cohorts of 100 and 101 year old produces the result of 1/2= 50%. Like incidence data, 
background morality is also integrated into the model in an age and gender-indexed table.  
 
5.4.3.2 Probability of death for other reasons for a gastric cancer patient 
 
As defined in 5.2.1, our target population is considered an aged cohort at baseline. Therefore, even 
though a subject is diagnosed with GC, there is still a high risk of dying of other causes such as 
cardiovascular disease (Guadagni et al. 1997), especially when GC is discovered later in life. As we 
model the lifetime experience of the target population, our Markov model has to take this issue into 
account (Figure 5-21, branch “Death for other reasons”).   
 
Figure 5-21. Death for other reasons of GC patients  
 
The probability of a GC patient dying of other causes is not the same as the probability of someone in 
the general population, particularly in the first few years after diagnosis when the probability of GC 
death is relatively high. Therefore, we estimated the probability of death for other reasons in our 
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target population following the approach outlined in the ‘Cost of Illness Handbook’. (U.S. 
Environmental Protection Agency 2010).  
 
Table 5-6. Probability composition of gastric cancer patients surviving through a given year  
p  w  
q1 q2 
 
Table 5-6 represents the cohort of GC patients who remain alive at the beginning of the year.  The 
area of the entire box is the probability of having survived to the beginning of the given year post-
diagnosis and assumes the probability of 100% at the initial Markov cycle.  That is, all probabilities 
described below are conditional on having survived to the beginning of this given year post-diagnosis. 
 p: The probability of a GC patient surviving through a given year post-diagnosis (GC survival 
rate for four clinical stages each)  
 q: The probability of dying of causes other than GC in a matched cohort in the general 
population (Life Table).  
 q = q1 + q2 , a mathematically hypothesized probability for calculation 
 q2: The proportion of the GC cohort who would die of other causes if they were not 
diagnosed with GC beforehand who instead die of GC.  
q2 = (q/(1-q) × (1-p-q) 
For a GC patient, the probability of GC death during the given year (Markov cycle) is 
PCancer = (1-p-q) + 0.5×q2 
The probability of death for other causes during the given year (Markov cycle) is  
POther = q - 0.5×q2  
The annual probability of death for other reasons is presented Table 5-7.  The cancer is still the main 
cause of death for a GC patient, despite the higher probability of death due to other reasons. As the 
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cancer becomes more advanced, the likelihood of dying of other reasons decreases which clearly is 
consistent with the clinical reality.  
 
Table 5-7. Pattern of death in gastric cancer patients (%) 
GC Stage GC Survival GC Death 
PCancer   
Death for Other Reasons 
POther 
Stage 1 96.56 2.09 1.35 
Stage 2 91.79 6.89 1.32 
Stage 3 82.01 16.74 1.25 
Stage 4 9.25 90.00 0.75 
 
5.4.4 Early detection by screening and surveillance   
From an epidemiological perspective, early detection by screening or surveillance manifests itself as a 
favorable shift of stage distribution in GC patient population. That is, there should be more early stage 
cases in GC patients detected by the program than in the GC patient cohort diagnosed under routine 
clinical practice.  In our model, we used two Dirichlet distributions to represent the stage-shift.  The 
first Dirichlet distribution describes the stage composition under routine care. Stage 1: Stage 2: Stage 
3: Stage 4:  corresponds to 7%:17%:33%:43% respectively (Figure 5-22) (Kim et al. 2000; Kubota et 
al. 2000; Nakashima et al. 2010).    
 
Figure 5-22. Stage distribution of gastric cancer patients diagnosed under usual care  
 
The second Dirichlet distribution describes the stage composition of GC patients detected by 
preventive programs.  The proportion of Stage 1, Stage 2, Stage 3 and Stage 4 patients are 85%, 4%, 8% 
and 3% respectively (Figure 5-23) (Koong et al. 1996; Wai et al. 2002).  It is assumed that the down-
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stage effect is independent of the frequency of follow-up OGD. So the second Dirichlet distribution   
was applied in the Markov tree for screening and surveillance. 
 
Figure 5-23. Stage distribution of gastric cancer patients detected by follow-up OGD 
 
We did not define the range for each stage proportion for deterministic sensitivity analysis because 
clinically, the cancer staging of Stage 1, Stage 2, Stage 3 or Stage 4 are not independent events. The 
sum of four proportions has to be one, which is called Coherence of Probability. Defining individual 
ranges could violate this requirement when TreeAge program runs the models. Using two Dirichlet 
distributions has another advantage, that is, the variations of four proportions for each clinical stage 
can be explored later using probabilistic sensitivity analysis sampling. 
  
5.4.5 Cost estimation  
We estimated the incremental cost related to operation of an OGD surveillance or screening program, 
initial diagnosis and treatment, and post-treatment follow-up of GC patients.  The main cost 
difference between preventive strategies and no OGD intervention is the expenditure on operating a 
screening or surveillance program. This expenditure is referred to as operational cost. Initial diagnosis 
and staging include gastrointestinal imaging, blood tests, endoscopy, biopsy, computed tomography 
scans and laparoscopy. GC treatment includes surgery, chemotherapy, radiation, and other general 
medical services. Post-treatment follow-up cost, in this case, includes blood tests, computed 




5.4.5.1 Operational cost and efficiency  
The costs of operating a screening or surveillance program or operational cost were primarily 
comprised of two parts; the clinical cost of OGD and biopsy, and the non-clinical cost of supporting 
activities in the delivery of the OGD program, which include establishment of infrastructure and 
delivery system, manpower, case management, quality control, transportation and subjects' salary loss 
due to program participation (Table 5-8). 
 
When estimating the clinical cost, we used the direct estimate from our precious study on cost 
efficiency of a OGD surveillance program for GC in Singapore (Zhou et al. 2013). For the non-
clinical or program cost, we used its proportion of total operational cost to represent it in the model. 
That is, program costs and clinical costs are compared in a way given a certain operational cost, like a 
fixed budget for a program. The above mentioned proportion practically serves as an indicator of 
operating efficiency of an actual program (Centers for Disease Control and Prevention 2005; 
Subramanian et al. 2011).   
 





Baseline OGD for 
surveillance strategy 
OGD/biopsy/ 
H. Pylori eradication 350 (175-750) 
 Follow-up OGD  OGD / biopsy 340 (170-680) (Zhou et al. 2013) 
Program cost (%)  Supporting activities  50% (20-80%) 
(Subramanian et al. 2011) 
(Centers for Disease Control and Prevention 2005) 
 
 
5.4.5.2 Treatment and follow-up cost  
 
When estimating treatment cost, we followed the instructions recommended in ‘The Cost of Illness 
Handbook’ (Environmental Protection Agency USA 2000). The instructions are stated as follows:  
1. Identify a cohort who has received the standard GC treatment. The hypothetical cohort 
consists of GC patients being treated in NUH, the not-for-profit tertiary medical institution 
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where physicians follow the international algorithm for GC treatment (Morabito,Carillio and 
Longo 2009). 
2. Determine the standard treatment elements and probability of receiving specific treatment 
components (Table 5-9).  
3. Aggregate the cost stream to obtain expected incremental cost of GC (Table 5-10) 
 
Expert opinion of Dr. Dan Yock Young, an expert in clinical gastroenterology and cost-effectiveness 
modeling at the NUH Singapore, was sought to ascertain treatment components for each clinical stage. 
Hospital charges were used to estimate the cost of treatment elements. The post-treatment follow-up 
costs encompassed all expenditures after initial diagnosis and aggressive treatment 
Table 5-9. Algorithm of stage specific gastric cancer treatment  
Stage Medical Components  Medical Service Mix 
Stage 1 
Endoscopic mucosal resection/  
Endoscopic submucosa dissection  
30% 
Total/subtotal gastrectomy 70% 
Stage 2a Total/subtotal gastrectomy 60% 
Stage 2b Total/subtotal gastrectomy + chemotherapy  40% 
Stage 3 Total/subtotal gastrectomy + chemotherapy  100% 
Stage 4 
Basic support care  30% 
Bypass surgery + chemotherapy  30% 
Chemotherapy  40% 
 
Table 5-10. Diagnostic cost and treatment cost by clinical stage  
Components 
Cost $ 
Mean (Range) Reference 
Diagnosis & staging for 
program detected GC cases* 740 (660 - 820) 
 Diagnosis & staging for 
clinically diagnosed GC cases † 1155 (960-1440) 
 Cost of treatment 
  Stage 1 20000 (10000 - 40000) (Hospital Case mix Records 2012) 
Stage 2 27200 (13600 - 54400) Expert opinion 
Stage 3 38000 (19000 - 76000) 
 
Stage 4 15500 (7800 - 31100) 
 Post-treatment follow-up 955 (900-1300) 
 CT, computed tomography; CXR, chest radiograph; ICU, intensive care unit 
* CT scan/CXR/ultrasound/blood test 




As cost data followed right-skewed distributions (Thompson and Barber 2000), base case estimates 
were halved and doubled to produce the range (Chang et al. 2012). Costs were expressed as 2012 
constant United States dollar ($) at an annual average exchange rate of 1.25 Singapore dollars.    
 
5.4.5.3 Cost assignment in TreeAge program  
 
The costs were assigned to the clinical events where medical resources were consumed. As shown in 
the Markov tree simulating surveillance pathway of high risk subjects (Figure 5-24), the follow-up 
OGD cost was assigned at step 1, the cost for confirmative tests was assigned at step 2, the stage-
specific treatment cost was assigned at step 3. As the model calculated the incremental cost, the cost 
for basic medical care and the terminal care prior to death was not taken into account. Thus no costs 
were assigned on the branches “Death for other reasons” and “OGD negative” representing high risk 
subjects not yet developing GC.    
 
Figure 5-24. Cost assignment in Markov trees 
 
 
5.4.6 Utility  
Health states free of GC in our model are assumed to be in full health, i.e., utility is 1 for these states. 
The death state is associated with a utility of zero. For GC patients in different clinical stages, their 
utility scores have been measured in CHAPTER IV: QUALITY OF LIFE OF PATIENTS WITH 
104 
 
GASTRIC CANCER. We used mean EQ-5D score of each clinical stage, which is anchored between 
0 (death) and 1 (full health), as stage-specific utility. Therefore in our model, utility for cancer, death 
and full health states are in coherence with each other. The stage-specific utilities are summarized in 
Table 5-11.  
 
In conformity to our assumption that, after diagnosis and initial treatment, GC patients remain stable 
until death, the utility of GC patients are constant until patient’s death. Considering the negative effect 
on the patients’ quality of life due to surgery or chemotherapy, we assumed a 6-month period when 
the utility is only half of that when the disease is stable (Munene et al. 2012). For both death due to 
GC or other reasons, we did not account for the utility deterioration three months before death 
(Environmental Protection Agency USA 2000).  
 
Table 5-11. Stage-specific utility of gastric cancer patients  
Clinical Stage Mean (95% CI) 
Percentile 
Disutility* 
10  25  50  75  90  
Stage 1 0.88  (0.77-0.98)  0.60 0.80 1 1 1 - 0.28 
Stage 2 0.86 (0.73 - 0.99) 0.46 0.71 1 1 1 - 0.29 
Stage 3 0.77 (0.58 - 0.95) 0.09 0.74 0.81 1 1 - 0.31 
Stage 4 0.68 (0.51 - 0.84) 0.12 0.46 0.80 1 1 - 0.33 




6 CHAPTER VI.  COST EFFECTIVENESS ANALYSIS -  MODEL 
VALIDATION & PROJECTIONS   
 
In Chapter V, we presented the detailed process of building a Markov model. The limitations and 
advantages were explained about using different data and assumptions. This practice meets the 
requirement for transparency and thus technically validates our model to a certain degree (Eddy et al. 
2012). For a model to provide useful qualitative or quantitative information, an official validation 
process is necessary and important whereby the model outputs are compared with the existing data for 
the consistency between them. Due to practical constraints, we conducted only the internal validation 
in the present project.  
 
6.1 Internal Validation of the Markov Model 
 
Regarding model validation, one has to take note that discrepancies between model outputs and the 
existing data are inevitable. In the case of our models, the primary discrepancy lies in the study design. 
We built cohort-based Markov models to simulate the target population of Singapore Chinese at 50-
69 years old. Such a model assumes that the population modeled is a static and homogeneous cohort, 
that is, the population will not increase or decrease due to reasons other than death either from GC or 
for other reasons. However, the real residential population in Singapore, which includes citizens and 
permanent residents, is a dynamic cohort with a fluctuating population size in response to government 
migration policies. Our target population, in particular, increased every year for the past two decades 
(Department of Statistics Singapore 2012). Therefore, even if our models are perfect in modeling a 
static cohort representing the target population, there will still be some discrepancies between model 




Internal validation was conducted to examine how well our models represent the target population in 
terms of epidemiological profile. The two most important variables are GC incidence and all-cause 
mortality. The TreeAge structures in  
Figure 5-7. Markov Model for the no OGD intervention,  
Figure 5-8. Markov Model for the screening strategy    
Figure 5-9. Markov Model for the surveillance strategy  
were adapted to calculate the age-specific GC incidences and all-cause mortality for validation against 
the population data reported by Singapore Cancer Registry and Department of Statistics Singapore.  
 
6.1.1 Validation of gastric cancer incidence  
 
Figure 6-1. Age-specific gastric cancer incidence of Singapore Chinese   
 
As shown in Figure 6-1, the incidences projected by the Markov models for the no OGD intervention, 
screening and surveillance strategies are almost same as the original data inputted with the four 
incidence curves overlapping with each other. This observation is in line with the theory that the 
screening and surveillance strategies are not supposed to affect GC development. It also indicates that 
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our models did not misestimate the GC incidences for each strategy. The chances are rare that the 
benefit of a screening or surveillance program would be biased by miscomputation of GC incidences.   
 
6.1.2  Validation of all-cause mortality  
 
Figure 6-2. Age-specific all-cause mortality of Singapore Chinese (original vs. model estimates) 
 
Age-specific mortalities were estimated by the three models and compared with the Life Table of the 
Singaporean Chinese. As in Figure 6-2, before the age of 70 years, the four mortality curves almost 
overlap with each other. Differences begin to appear after the age of 70 years with the screening and 
surveillance curves running below those of the Life Table and no OGD intervention, indicating the 
survival benefit due to these two preventive measures. However, the differences are subtle before the 
age of 82 years, which is the life expectancy of an average Singaporean Chinese. After that age 
threshold, the mortality reduction from the screening and surveillance strategy becomes more 
pronounced until the whole cohort dies.   
 
The fact that screening or surveillance strategies exhibit a survival benefit late in life is clinically 
plausible. This phenomenon is referred to as the “time-lag” effect of preventive measures in public 
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health. From an epidemiological point of view, GC-specific mortality accounts for barely 2% of all-
cause mortality in Singapore (Singapore Cancer Registry Committee 2010) which is the upper bound 
for mortality reduction potential due to a preventive strategy. This proportion is too small to 
immediately demonstrate the survival benefit by any preventive measure on a population level.  
 
6.2  Model Outputs in the Base-Case Scenario  
 
6.2.1 Cohort analysis   
For the target population of 50-69 year old Chinese, the overall lifetime risk of dying from GC was 
2.62%. Surveillance would reduce this risk by 33% to 1.76% while screening would further reduce it 
to 1.73% (Table 6-1). Given the target population size of 712,600 (Department of Statistics Singapore 
2012), the screening strategy would avoid 6342 deaths due to GC (male 3,787 and female 2,403) and 
surveillance would save 6128 lives from GC (male 3,859 and female 2,367). To realize these benefits, 
the surveillance strategy required 4.4 OGD examinations per person over a lifetime, which was 
approximately one third of OGD examinations (n=13.5 per person) required for the screening 
strategy.  
Table 6-1. Reduction in gastric cancer related death by the surveillance and screening strategies 
Population  Lifetime risk of death No OGD Surveillance Screening 
Whole cohort Other reasons (%) 96.65 97.28 97.32 
n=712,600 Gastric cancer (%) 2.62 1.76 1.73 
 
 GC deaths averted (n) 
 
6,128 6,342 
Male Other reasons (%) 95.94 96.73 96.70 
n=354,000 Gastric cancer (%) 3.38 2.29 2.31 
    GC deaths averted (n)   3,859 3,787 
Female Other reasons (%) 97.36 97.80 97.77 
n=358,600 Gastric cancer (%) 1.92 1.26 1.25 




6.2.2  Cost-effectiveness analysis     
Comparisons of the cost-effectiveness of the three strategies are illustrated in Figure 6-3. Under the 
reference strategy of no OGD intervention, each subject would experience 18.22 QALYs at the cost of 
$542. Focused surveillance in high risk subjects would acquire 0.0665 more QALYs at an additional 
cost of $1,998, resulting in an ICER of $30,033/QALY. Population screening compared to 
surveillance would cost $3,170 more with an additional benefit of 0.0075 QALYs. This would yield 
an ICER of up to $421,247 /QALY, more than nine times the WTP threshold of $46,200/QALY. 
Based on ICERs associated with the two competing strategies, surveillance would be considered cost-
effective in Singapore. Dominance or extended dominance, when one strategy is less effective but 
more expensive than another strategy or combination of strategies, was not exhibited in the 
comparisons.  
 
Figure 6-3. Comparing the cost effectiveness of no OGD intervention, 




6.2.3 Heterogeneity in cost effectiveness  
It is of public health significance to explore the heterogeneity in the cost effectiveness of screening 
and surveillance given different baseline GC risk and background mortality. Table 6-2 compares the 
cost, effectiveness and ICERs of screening and surveillance for age and gender subpopulations. 
Compared with the usual practice of no OGD intervention, surveillance is cost-effective with ICERs 
below $46,200/QALY for all subgroups except for females below 60 years old. The screening 
strategy is not cost-effective relative to surveillance as its ICERs are far more than $46,200/QALY 
and are not stable. As expected theoretically, males featured by higher GC risk and background 
mortality (Department of Statistics Singapore 2012; Singapore Cancer Registry Committee 2012) are 
associated with lower ICERs than those for females by a ratio of 2 to 5. Starting surveillance at an 
older age appears more cost-effective than at a younger age as shown by the negative relationship 
between cohort age and ICERs.  
 
For the reference strategy, the older age groups have incurred more cost than younger age groups, 
despite their shorter life expectancy (Table 6-2, column 2 and 3). This finding is seemingly count-
intuitive and is caused by discounting the future costs in the Markov model, a practice recommended 
for all economic evaluations. In simulating lifetime experience, future costs will be discounted every 
year to the present monetary value. Older age cohorts, who have much higher GC incidence, consume 
far more resources for treatment and post-treatment follow-up than younger age groups at the 
beginning. Therefore, the cost incurred at present is high. Although more money would be spent on 
younger age groups later on, it is discounted every year. Setting a discount rate as 0 will make 
younger age groups accumulate more cost than older age groups by a small margin. For the 
surveillance or screening strategies, follow-up OGD costs a larger amount of money every year so 
discounting does not show its effect. 
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Table 6-2. Heterogeneity of the three strategies by age and gender  
  No OGD Intervention Surveillance Screening  
  Cost ($) Utility (QALY) Cost ($) Utility (QALY) ICERs Cost ($) Utility (QALY) ICERs 
Whole cohort 
        Overall 546 18.223 2,820 18.290 34,187 6,764 18.297 84,027 
50-54 478 20.487 2,952 20.549 39,761 7,464 20.552 116,433 
55-59 538 18.617 2,839 18.687 33,046 6,890 18.690 90,743 
60-64 596 16.579 2,707 16.656 27,489 6,256 16.659 70,750 
 65-69 636 14.431 2,548 14.512 23,470 5,566 14.515 61,625 
Male                 
Overall 717 17.232 2,905 17.326 23,201 6,618 17.340 54,437 
50-54 625 19.573 3,019 19.660 27,668 7,317 19.669 66,920 
55-59 710 17.636 2,923 17.734 22,535 6,747 17.744 60,370 
60-64 789 15.544 2,808 15.653 18,502 6,122 15.665 44,442 
 65-69 850 13.368 2,666 13.485 15,531 5,443 13.494 38,275 
Female 
        Overall 389 19.141 2,749 19.187 50,852 6,910 19.191 130,160 
50-54 343 21.351 2,900 21.395 57,693 7,615 21.396 145,440 
55-59 382 19.529 2,772 19.578 49,156 7,035 19.578 133,060 
60-64 423 17.517 2,627 17.570 41,287 6,392 17.571 119,380 
 65-69 451 15.359 2,453 15.416 35,276 5,686 15.415 104,700 
ICER; Incremental cost effectiveness ratio. The unit for ICER is $/QALY.  
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6.3 Deterministic Sensitivity Analysis 
 
We compared outcomes of two scenarios when implementing the screening strategy. One scenario 
was that the whole target population undertook screening OGDs in alternative years, therefore the 
screening service would be provided intermittently. The other was that, as specified in Section 5.2.3.1, 
Endoscopic screening, two halves of the target population undertook screening OGDs in turn so that 
screening service would be provided in a continuous way. The second scenario has shown better cost-
effectiveness than the former.  
One-way sensitivity analysis was also applied to identify the factors with significant impact on the 
model results. The range for each parameter was based on the upper and lower bounds of biological 
plausibility as reported in the literature. We analyzed net health benefit (NHB) of each Markov model 
to quantify the impact of every parameter. Sensitivity analysis also helped to identify the possible 
thresholds of each parameter across which the choice of optimal strategy would have changed. 
Another function of deterministic sensitivity analysis is to examine the model assumptions against the 
current clinical and economic understanding. We did not run sensitivity analyses on GC incidence 
because its variations have been well represented by specific values across age and gender 
subpopulations.  
 
In none of scenarios during the univariate sensitivity analysis was screening the cost-effective 
strategy. The optimal strategy is a choice between surveillance and no OGD intervention. The base-
case finding that surveillance is cost-effective in the Singapore healthcare system is quite robust to 
most parameters populating the model. If the range of a parameter is able to cause a 0.2 QALY 




Sensitivity analysis identified nine such parameters which are listed in deceasing order of magnitude 
in Table 6-3. As anticipated a priori, the discount rate, age of starting surveillance, cost of follow-up 
OGD and baseline OGD, and proportion of program cost are negatively related to surveillance NHB, 
while the OR of high risk subjects, prevalence of premalignant lesions and utility of GC Stage 1 have 
positive correlations with surveillance. These relationships are very useful in customizing an actual 
program in consideration of the practical limitations.  
 
Table 6-3. Parameters impactful on net health benefit of surveillance strategy identified by 
sensitivity analysis   
Input parameters  Range Variation of  
Surveillance NHB  
Relationship with  
Surveillance NHB 
Threshold 
Discount rate (%) 0-5 12.64 Negative 
 
Age (years) 50-69 7.68 Negative - 
Willingness-to-pay 
 ($1000/QALY) 
15-100 0.15 Positive >30.3 
Odds ratio of 
high risk subjects 
2.4-21.5 0.09 Positive > 3.11 
Program cost Proportion (%) 20-80 0.06 Negative < 67 
Utility of GC Stage 1 0.6-1 0.05 Positive > 0.63 
Cost of follow-up OGD ($) 170-680 0.04 Negative < 624 
Prevalence of premalignancy (%) 6.8-48.2 0.03 Positive - 





6.3.1 Discount Rate  
 
 
Figure 6-4. Net Health Benefit variation across the range of the discount rate  
 
Discount rate is an economic parameter gauging the time-preference of Singapore society. It appears 
to be the most influential parameter for the model. Varying the discount rate from 0 to 5% would 
cause a reduction of approximately 50% of NHBs for all the three strategies. Although NHB changes 
dramatically by the discounting, the choice of optimal strategy is robust to the discount rates 




6.3.2 Age of starting OGD follow-up 
 
 
 Figure 6-5. Net Health Benefit variation across the range of age starting follow-up 
 
Age at which OGD follow-up starts is the second most influential factor. The negative relationship 
between NHBs and starting age is expected which means starting the intervention at an earlier time 
can harvest more healthy years. Our model projected that an individual undertaking OGD 
examination at the age of 50 years would generate 7.68 QALYs more than when he undertakes it at 
age of 69 years for the surveillance strategy. However, this huge variation in NHBs associated with 
the starting age does not change the choice of optimal strategy which is the surveillance strategy in 








 Figure 6-6. Net Health Benefit variation across the range of willingness-to-pay  
 
WTP is another economic parameter which is Singapore-specific in our model. Unlike discount rate 
and starting age that affect all the three strategies equally, WTP exerts different influences in terms of 
NHB generation (Figure 6-6). As the WTP grows, indicating that a healthcare system is willing to pay 
more for health, both surveillance and screening would create more and more health years with the 
latter at a faster pace. However, the increase of WTP has little effect on the reference strategy. 
Comparing surveillance with no OGD intervention, a threshold of 30,300 $/QALY was identified 






6.3.4 Odds ratio  
 
 
 Figure 6-7. Net Health Benefit variation across the range of odds ratio of high risk subjects in 
the surveillance strategy 
 
Odds ratio (OR) was used to differentiate high and low risk subjects from the target population for the 
surveillance strategy. The OR ranges widely from 2.4 to 21.5 to represent various precancerous 
lesions from chronic atrophic gastritis to gastric mucosa dysplasia (Watabe et al. 2005). Figure 6-7 
displays an upward trend of NHB with increasing ORs which means that the surveillance strategy 
works more efficiently for more susceptible subpopulations. These results are biologically expected. 
As OR is not one of the input parameters for no OGD intervention and screening, their NHBs remain 
constant. An OR of 3.11, the GC risk of patients with atrophic gastritis, was discovered to be the 




6.3.5 Program cost  
 
 
 Figure 6-8. Net Health Benefit variation across the range of proportion of program cost of 
operational cost 
 
Program cost measures the resources used in supporting activities to deliver the essential clinical 
services, which are OGD examinations in our study. From the perspective of program evaluation, 
program cost serves as an indicator of the operating efficiency of a program. Judging by definition, 
less program cost means better operating efficiency. Our model represents the program cost as a 
proportion of total operational cost.  
 
As shown in Figure 6-8, program cost is able to influence both screening and surveillance strategies.  
The screening strategy is more sensitive to program cost than the surveillance strategy because it 
needs to carry out far more follow-up OGDs. As expected theoretically, a higher proportion is 
associated with a lower NHB. Our model further suggested a threshold of 67% for a surveillance 




6.3.6 Utility of gastric cancer stage 1 
 
 
 Figure 6-9.  NHB variation across the range of utility of Stage 1 gastric cancer patients 
 
 Utility of Stage 1 GC patients reflects the clinical outcome of managing early GC cases in Singapore. 
Sensitivity analysis (Figure 6-9) demonstrates a positive linear relationship between the utility of early 
GC patients and NHBs of the three strategies. This positive relationship validates our model in the 
sense that better clinical outcomes lead to more health gain from strategies evaluated. It is expected 
that the slope for the no OGD intervention strategy is the lowest; because the surveillance and 
screening strategies are supposed to produce more Stage 1 patients than no OGD intervention. 






6.3.7 Cost of follow-up OGD  
 
 
 Figure 6-10. Net Health Benefit variation across the range of follow-up OGD cost  
 
As shown in Figure 6-10, follow-up OGD cost negatively influences the model output of the 
surveillance and screening strategies. The slope for the screening strategy is steeper than that for 
surveillance implying that the former was more sensitive to follow-up OGD cost than the latter. This 
is due to the fact that the screening strategy needs more follow-up OGDs than the surveillance by 
examining half of the target population ever year (5.2.3.1: Endoscopic screening). Regarding the 
choice of optimal strategy, surveillance would be cost-effective if follow-up OGD price can be 





6.3.8 Cost of baseline OGD 
 
 
Figure 6-11. Net Health Benefit variation across the range of baseline OGD cost of the 
surveillance strategy 
 
Baseline OGD was used in the surveillance strategy to categorize the target population. As shown in 
Figure 6-11, given the fixed WTP of $46,200/QALY, increasing the baseline OGD cost will reduce 
QALYs produced by the surveillance. Its advantage over no OGD intervention and screening shrinks. 
Covering the full range of baseline OGD price from $350 to $ 1400, surveillance persists as the cost-





6.3.9 Prevalence of precancerous gastric lesions  
 
 
Figure 6-12: Net Health Benefit variation across the range of prevalence of gastric precancerous 
lesions 
 
Variation of the prevalence of gastric precancerous lesions represents the fact that the potential burden 
by GC disease is different in different groups. Within the range of 6.8% to 27%, NHB from the 
surveillance strategy increases with the growing prevalence of precancerous lesions (Figure 6-12). 
This upward trend highlights that the surveillance strategy should be preferably implemented in a 






6.4 Probabilistic Sensitivity Analysis  
 
To assess the influence of uncertainties associated with the parameter estimates, we conducted a 
probabilistic sensitivity analysis (PSA) with 1000 Monte Carlo simulations by sampling distributions 
of nine parameters individually or collectively (Table 6-4). We chose not to analyze all parameters for 
two reasons, (1) it is unnecessary to introduce too many uncertainties in the model; and (2) parameters 
like proportion of program cost and cost of follow-up OGD and GC treatment are arbitrary and their 
estimates therefore are not associated with sampling error.   
 
The nine parameters chosen were the prevalence of precancerous lesions, the OR for GC of high risk 
relative to low risk, utility scores of the four clinical stages, and stage compositions of GC cases 
detected with or without OGD intervention. The Bayesian posterior distributions were assigned to 
these parameters after examining the statistical properties of the point estimates. The individual 
variation of age starting OGD follow-up was reflected by the actual age distribution of the target 
population at baseline. The possibility of being the cost-effective strategy given different WTPs was 
plotted as a cost-effectiveness acceptability curve (CEAC) for the three strategies. 
 
Table 6-4. Distributions assigned to parameters in probabilistic sensitivity analysis   
Input Variables Type of Distribution Mean (S.D) 
Utility Score  
  Stage 1 Gamma
*
 0.88 (0.05) 
Stage 2 Gamma
*
 0.86 (0.07) 
Stage 3 Gamma
*
 0.77 (0.10) 
Stage 4 Gamma
*





 6.00 (2.46) 
Prevalence of premalignant gastric lesions (%) Beta
*
 13.5 (6.75) 
Stage distribution of GC cases(Stage 1:2:3:4) 
  Population with OGD follow-up Dirichlet 85%:4%:8%:3% 
Population without OGD follow-up Dirichlet 7%:17%:33%:43% 
Age of starting OGD Actual distribution  
 
*  Methods of moments; S.D: standard deviation  
† 




6.4.1 Utility of gastric cancer patients at each clinical stage  
Utility scores are special parameters in terms of their range. Theoretically, it can assume any value 
from negative infinity (worse than death) to the natural upper constraint of 1 (full health). To fit utility 
score in PSA, a simple transformation 1-Utility is employed so that the derived variable 1-Utility 
follows a gamma distribution with a range of 0 to positive infinity.  
 
Utility information is usually provided by a quality of life study. The stage-specific EQ-5D scores in 
CHAPTER IV: QUALITY OF LIFE OF PATIENTS WITH GASTRIC CANCER were used to 
represent the utility of Singapore Chinese patients with GC in our model. The two parameters for 
gamma distributions (α, λ) were estimated by methods of moments approach using means and 
standard deviations of EQ-5D for each GC stage.  
 
6.4.1.1 Distributions sampled in probabilistic sensitivity analysis for utility scores of 
gastric cancer patients at four clinical stages.  
  
Figure 6-13, Figure 6-14, Figure 6-15 and Figure 6-16 below display the gamma distributions 
representing the randomness associated with utility estimates for each GC stage.   
 
 




Figure 6-14. Simulated Gamma (151, 176) of the utility of Stage 2 patients   
 
 
Figure 6-15. Simulated Gamma (60, 77) of the utility of Stage 3 patients   
 
 




As explained in the beginning of this section, the above distributions are not EQ-5D distributions 
observed in CHAPTER IV: QUALITY OF LIFE OF PATIENTS WITH GASTRIC CANCER, 
but theoretical distributions generated by the TreeAge program based on the EQ-5D results.    
 
6.4.1.2 Cost-effectiveness acceptance curves for individual distributions of the four clinical 
stages  
 
The CEACs derived by PSA sampling individual distributions are presented for each clinical stage. 
After incorporating the uncertainty surounding  the utilities of Stage 2, Stage 3 and Stage 4 GC 
patients, the probability of surveillance being the cost-effective strategy is one at the Singapore-
specific WTP of 46,200 $/QALY (vertical line in Figure 6-17, Figure 6-18 and Figure 6-19). This 
probability is slightly lower at 99.90% if the model accounts for only the uncertainty surounding the  




Figure 6-17. Probability of being cost-effective of the three strategies when accounting for 







 Figure 6-18. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding the utility of Stage 3 patients  
 
 
Figure 6-19. Probability of being cost-effective of three strategies when accounting for 





Figure 6-20. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding the utility of Stage 1 patients  
 
6.4.2 Distributions of gastric cancer stage  
 
Our model will generate two GC patient populations. The first population comprises GC patients 
diagnosed under usual care with the proportions of Stage 1, Stage 2, Stage 3 and Stage 4 GC cases 
being 7%, 17%, 33% and 43% respectively. The second population presents the GC patients detected 
through either the screening or surveillance strategy with stage compositions of 85%:4%:8%:3% for 
Stage 1:2:3:4.  As stated in 5.4.4 Early detection by screening and surveillance, two Dirichlet 
distributions, Dir (7:17:33:43) and Dir (85:4:8:3) were used to represent the uncertainties associated 
with the estimates for proportions of each GC stage for the two patient populations respectively.   
 
Figure 6-21 displays the proportion distribution of Stage 1 GC cases diagnosed under usual care in 
PSA sampling Dir (7:17:33:43). Figure 6-22 displays the proportion distribution of Stage 1 GC cases 





Figure 6-21. Simulated input distribution representing the proportion of Stage 1 cases among 
gastric cancer patients diagnosed under usual care 
 
 
Figure 6-22. Simulated input distribution representing the proportion of Stage 1 cases among 
the gastric cancer cohort detected by follow-up endoscopy 
 
With the above distributions incorporated, our model projected that surveillance is the cost-effective 




Figure 6-23. Probability of being cost-effective of three strategies when accounting for 
uncertainties surrounding stage compositions of gastric cancer cohort  




Figure 6-24.  Probability of being cost-effective for the three strategies when accounting for 





6.4.3 Odds ratio 
 
OR represents the excessive risk for GC associated with high risk projects in the surveillance strategy. 
It can take only positive values. The log-transformed OR follows a normal distribution. In our model, 
we fit its uncertainty with a lognormal distribution of N (1.79, 0.90) (Figure 6-25) according to the 
published data (Watabe et al. 2005).   
 
 
Figure 6-25. Simulated input distribution representing the odds ratio of high risk subjects in the 
surveillance strategy 
 
In Figure 6-26, it is clear that the precision of OR estimation affects the likelihood of being the cost-
effective strategy for all the three strategies. Increasing WTP will give advantage to the surveillance 
and screening strategies but decreases that probability for no OGD intervention. At the Singapore 
specific WTP (highlighted with a vertical line), the likelihood that surveillance is cost-effective is 




 Figure 6-26. Probability of being cost-effective for the three strategies given uncertainties 
surrounding the odds ratio 
 
6.4.4 Prevalence of precancerous lesions  
The prevalence of precancerous lesions indicates the potential GC burden of the target population. 
Prevalence as a proportion follows binomial distribution. Therefore, the beta distribution (3, 22) was 
used to fitting the uncertainty around this parameter in the  PSA (Figure 6-27).  
 
 




The uncertainty introduced by the current estimate of prevalence of precancerous lesions affects the 
likelihood of being cost-effective for no OGD intervention and for surveillance. With the increase of 
WTP, surveillance is more likely to be preferred than no OGD intervention. Given the present model 
structure for Singapore Chinese, the probability of surveillance being cost-effective is 95.8% (vertical 
line in Figure 6-28).   
 
 Figure 6-28. Probability of being cost-effective of the three strategies when accounting for 
uncertainties surrounding prevalence of precancerous lesions.  
 
6.4.5 Age of starting OGD intervention  
Unlike the previous eight parameters submitted for PSA to quantify the influence of uncertainty 
associated with point estimates, age starting OGD follow-up represents the actual age variation among 
individuals of the target population. This type of variation is referred to as individual variability. To 
measure its effect on decision making, the original age distribution (Table 6-5) rather than a 




Table 6-5. Population size by age and gender (1000) 
Age Overall Males Females 
50 - 54 237.7    119.1    118.6    
55 - 59 209.0    104.7    104.3    
60 - 64 171.1    84.5    86.6    
65 - 69 94.8    45.7    49.1    
(Department of Statistics Singapore 2012) 
In the CEAC by PSA for starting age (Figure 6-29), the probability of the surveillance being the cost-
effective strategy is 88.8% for Singapore Chinese. The probability increases if the Singapore 
healthcare system is willing to pay more for health.  
 
 Figure 6-29. Probability of being cost-effective for the three strategies given the age variation 
among individuals of the target population  
 
In summary, the uncertainties in decision making contributed by individual parameters differ greatly 
as illustrated by the previous CEACs. Three parameters, OR of high risk subjects for GC, prevalence 
of precancerous lesions and initial age starting OGD follow-up, exert a stronger effect on the 
robustness of the choice of optimal strategy. To make an informed decision, we need to understand 
how these nine parameters and the complex interactions among them jointly contributed to the overall 
uncertainties in decision-making within the defined Markov structure.   
135 
 
6.4.6 Overall uncertainty in decision making  
 
Figure 6-30. Probability of being cost-effective of the three strategies accounting for 




After accounting for the joint-uncertainties contributed by the stage-specific utilities, the ORs, the 
prevalence of premalignant lesions and the stage compositions of GC cases, the probability of 
surveillance being cost-effective is 71.2% at the Singapore WTP threshold of $46,200/QALY (Figure 
6-30). Increasing WTP from $15,000/QALY to $54,950/QALY enhances the probability from 12.1% 
to 73.4%, but no further. Below the WTP threshold of $28,600/QALY, as reported in some Asian 




7 CHAPTER VII:  COST-EFFECTIVENESS ANALYSIS -CONCLUSION 
AND FUTURE WORK  
 
7.1 Overall Assessment of Endoscopic Surveillance for Gastric Cancer  
 
In countries with low to intermediate risk for GC, endoscopic surveillance of precancerous lesions has 
emerged as an effective and cost-effective strategy for GC prevention. To evaluate the applicability of 
this strategy to the Singapore healthcare system, we simulated the clinical experience of 50-69 year 
old Singaporean Chinese at risk of GC. According to our model, focused surveillance using 
endoscopy is a cost-effective modality compared to population screening. Relative to the usual 
practice of no OGD intervention, surveillance of the 50-69 year old Chinese population would yield 
an ICER of $30,033/QALY, which is considered cost-effective against the Singapore-specific WTP of 
$46,200/QALY and far below the ICER of $421,247/QALY for screening.  
 
The delivery capacity of a healthcare system plays an important role in program implementation. In 
this regard, surveillance is suggested by our model to be the preferred strategy over screening as the 
former appears to be less resource intensive and is thus easier for implementation. To avoid similar 
number of GC deaths in Singapore, our model projected that the number of OGD examinations 
required is 13.5 and 4.4 for screening and surveillance respectively during a participant’s lifetime. 
Therefore, population-based screening would likely cause a strain on many healthcare systems due to 
insufficient supply of facilities and qualified endoscopists as it has occurred in some jurisdictions such 
as Japan (Leung et al. 2008). Additionally, focused surveillance tends to be structured as a hospital-
based service, for example the GCEP in Singapore (Zhou et al. 2013), which has shown to be 
practical and efficient for easy subject recruitment and participation (Chien and Khan 2001). 
Delivering endoscopic GC surveillance in a hospital-based structure has been proven effective and 




7.2 Heterogeneity of Endoscopic Surveillance  
 
Given the unique GC risk and all-cause mortality related to age and gender (Department of Statistics 
Singapore 2012; Singapore Cancer Registry Committee 2012), we explored the heterogeneity of 
surveillance to inform resource allocation and priority setting among various demographical 
subgroups. From an economic perspective, resources are prioritized to the areas with lower ICER 
estimates which imply a better return on investment. Therefore, the 65-69 year old male group with 
the lowest ICER of $15,285/QALY achieved by surveillance should be favorably considered as a 
target group for implementing the program. This finding is consistent with a previous model which 
suggested that the age of 65 years is the optimal age to start OGD follow-up for GC prevention (Dan, 
So and Yeoh 2006). As male gender and older age are found to be associated with lower ICERs, 
resources may be allocated to these subpopulations when scaling up a surveillance program.  
 
7.3  Influential Factors for Program Implementation  
 
Through sensitivity analysis, we identified several influential parameters and their relationship with 
the clinical potential of the surveillance strategy. With this information available to the policy-maker, 
it is a matter of adjusting and monitoring these parameters to gain the maximum QALYs from a 
surveillance program. Although varying discount rate and age of starting OGD follow-up can 
dramatically change the QALY output, the surveillance strategy retains its cost-effectiveness.  This 
demonstrates that the choice of optimal strategy based on our model is quite robust to most influential 
factors. It has to be noted that, by discounting both cost and effectiveness at the same constant rate, 
our model underestimated the benefits of surveillance (Bonneux and Birnie 2001). However, being 
the standard practice in economic evaluation, discounting both allows for meaningful comparisons of 
ICERs between GC prevention and other public health programs, for example, the existing national 
screening programs for cervical cancer, colon cancer and breast cancer in Singapore (Yeoh, Chew and 
Wang 2006).   
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One central issue for GC surveillance is to define the appropriate precancerous lesions for continuing 
investigation. Following Correa’s model of GC development (Correa 1992), atrophic gastritis, 
intestinal metaplasia and dysplasia are perceived as premalignant GC lesions and are consequently 
suggested for OGD follow-up and further investigation (Kapadia 2003). However, the American 
Society of Gastrointestinal Endoscopy excluded atrophic gastritis (Hirota et al. 2006), and some 
researchers excluded Type I and Type II intestinal metaplasia as indications for OGD follow-up 
(Rugge et al. 2003). Our model employed OR to distinguish high risk groups from the general 
population. The sensitivity analysis suggested that the premalignant lesions associated with an OR of 
3.11 or above would produce favorable cost-effectiveness ratios for surveillance strategy. Considering 
epidemiologic evidence showing that the risk of GC associated with atrophic gastritis, intestinal 
metaplasia and dysplasia are all higher than 3.11 (Uemura et al. 2001; Vannella et al. 2010; Watabe et 
al. 2005), our findings support the practice of monitoring most clinically suspected premalignant GC 
lesions.  Moreover, it is implied that OGD surveillance could be extended to other subpopulations, 
such as those with a positive family history (Huang and Hunt 2003).  
 
In our study, the program cost proportion of total operating cost not only represents the magnitude of 
expenditure on supporting activities in the delivery of endoscopic surveillance, but also highlights the 
competition for resources between supporting activities and essential medical services of OGD 
examination (Subramanian et al. 2011). Our model examined this proportion as a parameter indicating 
operational efficiency of an actual program. According to the sensitivity analysis, the proportion of 
program cost cannot exceed 67% of total operation budget. Otherwise, a surveillance program would 
be considered inefficient in its operation and generate ICERs above the Singapore WTP. As such, the 
program cost proportion of 67% can be set as the standard to assess the actual performance of an 
OGD surveillance program in Singapore, such as the GCEP (Zhou et al. 2013). A similar approach 




Utility of stage 1 GC patients was found to be an influential parameter in our model. This provides 
evidence of the credibility of our model as this finding reflects one of the principles of secondary 
prevention, i.e., better clinical outcomes can be achieved when clinical interventions are administered 
at earlier stages (Leon Gordis 2009). The EQ-5D score of 0.63 was identified as the minimum utility 
of early stage GC patients for a cost-effective surveillance program in Singapore. For Stage 1 GC 
patients, a EQ-5D score of 0.88 has been reported previously by our research group (Zhou et al. 2012). 
A better quality of life for patients could be anticipated if a surveillance program was fully functional. 
Evidence have shown that GC patients detected by prevention programs are more likely to receive 
endoscopic procedures which would result in better outcomes than conventional surgery-based 
regimens (Ang,Khor and Gotoda 2010; Nam et al. 2009). Assigning the same utility to GC patients 
for the three strategies compared in our model, we intentionally based our choice of the surveillance 
strategy on conservative cost-effective ratios.   
 
The cost of OGD in our study has a great impact on cost-effectiveness estimation as in the model by 
Dan et al (Dan, So and Yeoh 2006). According to our model, endoscopic surveillance would become 
too expensive for Singapore healthcare system when the OGD cost raises above $624. Considering 
that the OGD cost in Singapore is one of the most expensive in Asia, OGD-based surveillance may 
not appear attractive to policy-makers. However, this parameter is the modifiable factor suggesting 
that OGD cost can be determined by health policy and healthcare market. In our model for example, 
OGD examination is cost at $340 which was the result of negotiation between the GCEP and the 
National University Hospital. It is cheaper than the normal hospital rate (Zhou et al. 2013).   
 
7.4 Robustness of the Findings 
 
Endoscopic surveillance appears to be the cost-effective given the ICERs estimated in our model. 
However, a decision solely based on a fixed ICER is premature considering the inherent imperfection 
with the estimates for input parameters. The PSA in our study has quantified the extent to which 
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uncertainties of the nine parameters have influenced our decision. As shown in the cost-effectiveness 
acceptability curve Figure 6-30, we are 71.2% confident that surveillance is the optimal strategy for 
GC prevention in Singapore. The likelihood favoring screening or no OGD intervention is 5.1% and 
23.7% respectively. The acceptability curve also showed that, based on the reported WTP thresholds, 
OGD surveillance may not be a better choice than currently no OGD intervention in developing 
countries of Asia. As confirmed in a Taiwanese population, an H. pylori eradication strategy was 
preferred over endoscopic surveillance (Lee et al. 2007).   
 
7.5 Strength and Limitation  
 
A few strengths about this project are noted. The most significant characteristic is that we investigated 
both utility and cost of the target population for this model. Allowing for future implementation, we 
represented program cost as a proportion of operating cost in order to inform program operation. For 
the surveillance strategy, we employed the OR rather than the progression rate to categorize the target 
population on the basis of GC risk, thereby providing evidence to identify appropriate people for 
OGD follow-up.  
 
Nevertheless, the study does have some limitations. To mitigate the lead-time bias and length-time 
bias toward screening or surveillance, GC patients were assumed to have the same survival experience 
whether they have been detected favorably by prevention programs. We also adjusted the structure of 
the Markov trees to ensure consistent GC incidences across three strategies. As a result, extra survival 
caused by length-time and lead-time bias was alleviated for screening or surveillance. However we 
cannot completely rule out their existence. Furthermore, we assumed a 100% compliance rate with the 
OGD schedule, which is unlikely in reality (Choi et al. 2009; Kwon et al. 2009). However, in the 
present situation, this study aims to provide a conceptual assessment of the cost-effectiveness 
potential of a surveillance strategy for future program implementation. To this end, our model has 
provided useful data to avoid conceptual deficit (Shapiro 1982).   
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7.6  Conclusion    
 
In conclusion, endoscopic surveillance of premalignant gastric lesions is potentially a cost-effective 
strategy for GC control for populations with low to intermediate risk, such as the Singaporean 
Chinese. To realize this potential, correct identification of high-risk subjects, efficient program 
operation and the utility of early GC cases are important concerns for program implementation. 
Policy-makers also need to consider the issues specific to their healthcare systems, such as the cost of 
providing the OGD service, discount rate and WTP threshold adopted by the society. Despite several 
concerns, potentially endoscopic surveillance is still the optimal strategy for these populations.   
 
7.7 Future Work  
 
As seen in the process of model construction (CHAPTER V:  COST EFFECTIVENESS 
ANALYSIS -    MARKOV MODEL CONSTRUCTION), the model validity is largely constrained 
by the availability of data. To improve the validity and usefulness of our model, the following studies 
would be greatly beneficial.  
 
7.7.1 Cost of illness of gastric cancer  
A well-designed cost of illness study investigating lifetime cost of a GC patient is necessary. Cancer 
disease is a lifetime disease. Once diagnosed, a life-long medical care is required, strictly meaning a 
life-long medical cost until the death. This imposes a tremendous economic burden on individual 
cancer patients and the society. Besides medical factors, many non-medical factors also increase this 
economic burden even when they do not necessarily affect the disease progression, such as inflation 
or lack of family care. A cost of illness analysis is able to measure the resources consumed in initial, 
maintenance and terminal stage of a GC patient. The analysis will not only quantify the expected cost 
of an average GC patient, but also identify medical and non-medical factors affecting cost generation. 
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With such a study in place, the current model would greatly improve the reliability and precision of 
model outputs. The findings can be interpreted in a quantitative manner.   
 
7.7.2 In-hospital mortality of a gastric cancer patient 
In-hospital mortality stands by itself an informative parameter of quality of care. It is theoretically 
intuitive that in-hospital mortality, which could be a result of various factors relevant to surgery, peri- 
and post-operative care, and basic medical care, can affect the costs and quality of life immediately 
and for a long time. As of completion of the present study, in-hospital mortality data have not been 
reported in Singapore. A study estimating in-hospital morality and predictive factors will improve our 
model dramatically.  
 
7.7.3 Prevalence of precancerous lesions   
As the fundamental epidemiologic basis for GC surveillance, prevalence of precancerous lesions 
should be derived from a population-based survey. However, such a study is not available for 
Singapore Chinese population. Our model was obliged to use an estimate jointly determined by GCEP 
(Zhu et al. 2009), a small community survey (Ang et al. 2005) and model calibration. A cross-
sectional survey should be conducted to investigate histologic prevalence of gastric premalignancies 
in the target population and different subgroups. When it comes to program implementation, this 
information will be very useful for resources allocation and priority setting.  
 
7.7.4 A model based on a dynamic cohort 
The current cohort-based model simulates a static cohort neglecting the fact that the target population 
is evolving constantly. Naturally a model based on a dynamic population is more appropriate and 
meaningful, which allows for the population changes due to economic and social reasons. The value 
of current model is somewhat undermined by the possibility that the model may miss out important 
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factors capable of affecting cost-effectiveness of the evaluated strategies. A discrete event model 
simulating a dynamic population is in the planning phase.  
 
7.7.5 An empirical model based on GCEP   
The follow-up of GCEP subjects is still ongoing. GCEP is a comprehensive project which is supposed 
to capture the information about GC incidence and mortality, progression rates of major precancerous 
lesions and all-cause mortality for high risk subjects. The data from such a real prospective cohort is 
ideal for an empirical model.   
 
The current model attempted to be an empirical model in the beginning. At the time of model 
construction, however, the GCEP follow-up is not sufficiently long to produce reliable data. Once the 
GCEP is completed, the current model will incorporate the updated information and evolve into a 
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